Document:

EX-10.1

 Exhibit 10.1 

 
  

 
 LICENSE AND DISTRIBUTION
AGREEMENT 
 between 
 CHIESI FARMACEUTICI S.p.A. 
 and 

CORNERSTONE THERAPEUTICS INC. 
 Dated November 6, 2012 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 ARTICLE 1
	 	DEFINITIONS	  	 	2	  
			
	 ARTICLE 2
	 	GRANT	  	 	6	  
			
	 ARTICLE 3
	 	OBLIGATIONS OF CORNERSTONE	  	 	6	  
			
	 ARTICLE 4
	 	PRODUCT DEVELOPMENT, MARKETING AUTHORIZATION AND PHARMACOVIGILANCE	  	 	8	  
			
	 ARTICLE 5
	 	SUPPLY AND MANUFACTURING	  	 	10	  
			
	 ARTICLE 6
	 	FINANCIAL PROVISIONS	  	 	16	  
			
	 ARTICLE 7
	 	MARKETING OF THE PRODUCT	  	 	18	  
			
	 ARTICLE 8
	 	INTELLECTUAL PROPERTY	  	 	19	  
			
	 ARTICLE 9
	 	REPRESENTATIONS, WARRANTIES AND COVENANTS	  	 	22	  
			
	 ARTICLE 10
	 	INDEMNIFICATION	  	 	25	  
			
	 ARTICLE 11
	 	CONFIDENTIALITY	  	 	26	  
			
	 ARTICLE 12
	 	TERM AND TERMINATION	  	 	27	  
			
	 ARTICLE 13
	 	GENERAL PROVISIONS	  	 	29	  

  
 i 

 LICENSE AND DISTRIBUTION AGREEMENT 

This LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”) is made as of this 6th day of November, 2012 (the “Effective Date”)
between Chiesi Farmaceutici S.p.A. a company incorporated under the laws of Italy, with its principal place of business at Via Palermo 26/A, 43122 Parma, Italy (“Chiesi”) and Cornerstone Therapeutics Inc. a corporation
incorporated under the laws of Delaware, with its principal place of business at 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518, USA (“Cornerstone”, and together with Chiesi, the “Parties”, each a
“Party”). 
 WITNESSETH 
 WHEREAS, Chiesi has developed the Product (hereinafter defined) and Chiesi owns or Controls (hereinafter defined) the entire right, title and interest to the Know-How (hereinafter defined), the
Patents (hereinafter defined) and the Trademark (hereinafter defined), all of them relevant to the Product, and the right to their exploitation in the Territory (hereinafter defined); 

WHEREAS, Chiesi has already submitted an NDA (hereinafter defined) for the Product in the Territory; 

WHEREAS, Cornerstone has experience in the distribution, marketing and selling of ethical pharmaceutical specialties for
respiratory diseases and related markets in the Territory; 
 WHEREAS, Chiesi and Cornerstone have agreed to enter into
this Agreement, pursuant to which Cornerstone will obtain a license from Chiesi for the purpose of having made, importing, storing, handling, using, promoting, distributing, marketing, offering for sale and selling the Product under the Trademark in
the Territory; and 
 WHEREAS, the Parties intend to enter into separate Pharmacovigilance Agreement (hereinafter
defined). 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and intending to
be bound, and it being understood that the above recitals shall be deemed to be incorporated into and form part of this Agreement, the Parties hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 

1.1 “Act” means the US Federal Food, Drug and Cosmetic Act of 1938, the Public Health Service Act of 1944 and the
regulations promulgated under those Acts, as may be amended from time to time. 
 1.2 “Affiliate” shall
mean, with respect to any person, any other person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with the person specified. For this purpose, the term “control”
(including the terms “controlling,” “controlled by” and “under common control with”) means possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person,
whether through the ownership of voting securities, by contract or otherwise. 

  
 1 

 1.3 “Agency” means any applicable supra-national, federal, national,
regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the manufacture, packaging, labeling, testing, release,
storage, handling, sale, distribution or use of the Product, including the FDA. 
 1.4 “Applicable Laws”
means the Act and other laws, rules and regulations, (including any rules, regulations, guidelines or other requirements of any Agency) applicable to the manufacture, packaging, labeling, testing, release, storage, handling, sale, distribution or
use of pharmaceutical products, as may be in effect from time to time in the Territory. 
 1.5 “Business
Day” shall mean any day other than a Saturday, Sunday or other day on which commercial banks located in New York City, New York are required or permitted by law to be closed for the conduct of regular banking business. 

1.6 “Calendar Month” shall mean a single month starting on the first day of each month and ending on the last day
of that same month. “Calendar Quarter” shall mean the 3 month period beginning on January 1 and ending on March 31; the period beginning on April 1 and ending on June 30; the period beginning on July 1 and
ending on September 30; or the period beginning on October 1 and ending on December 31. 
 1.7
“Claims” shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims and demands. 
 1.8 “Competitive Field” shall mean the treatment or management of cystic fibrosis patients. 
 1.9 “Competitive Product” shall mean any antibiotic product which is approved for the treatment or management of chronic pulmonary infections due to “Pseudomonas
Aeruginosa”.  
 1.10 “Compound” shall mean the active ingredient known as
“Tobramycin”. 
 1.11 “Controlled” or “to Control”, in relation to any
Intellectual Property Rights shall mean such Intellectual Property Rights in the possession (whether by ownership, license or other right, other than pursuant to this Agreement) by a Party or its Affiliates with the ability to grant to the other
Party access and/or a license (or sublicense) as provided herein under such right without violating the terms of any agreement or other arrangement with any Third Party and without requiring any further consent from such Third Party. 

1.12 “Field of Use” shall mean all indications approved under the approved Marketing Authorization for the
Product in the Territory as the same shall be in effect at any time after the Transfer Date. 

  
 2 

 1.13 “First Commercial Sale” shall mean, with respect to the
Product, the first arm’s-length commercial sale for value to a Third Party after the Transfer Date. Sales for investigator initiated trials, named patient programs, test marketing, non-registrational studies or any similar instance where the
Product is supplied at cost or without charge shall not constitute a First Commercial Sale. For clarity, First Commercial Sale shall not include the distribution of demonstration or training units that are not able to be operated or intended to be
used as a Product. 
 1.14 “Force Majeure” shall mean in relation to either Party any occurrence beyond
the reasonable control of that Party. 
 1.15 “Improvement” shall mean any discovery, development,
invention, enhancement or modification, patentable or otherwise, relating in any way to the Product, including any analytical methodology, ingredients, preparation, presentation, means of delivery or administration, use or packaging of the Product.

 1.16 “IND(s)” shall mean any investigational new drug application filed with Regulatory Authorities
in the Territory for approval to perform a clinical trial. 
 1.17 “Intellectual Property Rights” shall
mean patents, trademarks, know-how, service marks, logos, trade names, rights in designs, copyright, domain names, utility models and other intellectual property rights, whether registered or unregistered, and including applications for
registration, and all rights or forms of protection having equivalent or similar effect in the Territory. 
 1.18
“Know-How” shall mean all information, procedures, instructions, techniques, data, technical information, knowledge and experience (including toxicological, pharmaceutical, clinical, non-clinical, medical data and health
registration data), designs, processing, specifications and technology to the extent necessary to distribute, sell, or offer for sale the Product in the Territory, whether in written, electronic or other form, as owned or Controlled by Chiesi.

 1.19 “Losses” shall mean any and all damages (including all incidental, consequential, statutory and
treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, liens, losses, and expenses (including court costs, interest and reasonable fees of attorneys,
accountants and other experts). 
 1.20 The “Manufacturing Agreement” shall mean the Commercial
Manufacturing Agreement with Catalent Pharma Solutions, LLC, attached as Exhibit B. 
 1.21 “Marketing
Authorization” shall mean all necessary regulatory and governmental approvals and registrations, including NDA approvals, that are required by an Agency to market, distribute, promote and sell the Product in the Territory. 

1.22 “Marketing Authorization Application(s)” shall mean any or all applications to a Regulatory Authority in the
Territory in order to obtain Marketing Authorization. 

  
 3 

 1.23 “NDA” shall mean (a) the single application or set of
applications for approval and/or pre-market approval to make and sell commercially in the United States a pharmaceutical product filed with the FDA, including all information included in Drug Master Files (DMFs) related to such application(s), and
any related registrations with or notifications to the FDA, and (b) all supplements and amendments that may be filed with respect to any of the foregoing. 
 1.24 “Net Sales” shall mean gross sales amount of the Product in finished packaging invoiced or otherwise fiscally charged by Cornerstone to unrelated Third Parties in the
Territory less (i) any trade, quantity or cash discounts in amounts customary in the trade allowed to customers, including but not limited to launch discounts and stocking fees, (ii) all sales or excise taxes, duties and similar charges
made or incurred by reference to the sale of the Product by Cornerstone, (iii) chargeback payments, rebates, fees, GPO (group purchasing organization) administrative fees, and other similar adjustments for the Product, including those granted
on price adjustments, billing errors, reimbursements distribution fees, bona fide service fees, or similar payments granted or given to Third Party wholesalers or other Third Party distributors, buying groups, specialty pharmacies, health insurance
carriers or other institutions, including those paid in connection with such sales to any governmental entity or under a government program, (iv) freight, postage, shipping, insurance and other transportation charges to the extent included in
the invoice price, and (v) customary allowances or credits, not exceeding the original billing or invoice amount, granted by Cornerstone on account of claims, spoiled, damaged, rejected, recalled, or returned Product (vi) credit card
processing charges and bank fees associated with orders of Product and (vii) any amounts actually written off or specifically identified as uncollectible in accordance with GAAP. 

1.25 “Net Sales Price” shall mean the Net Sales during the previous Calendar Month/Quarter in the Territory
divided by the total number of units of Product to which such Net Sales were attributable. 
 1.26 “Orange
Book” shall mean the listing maintained by the FDA and referenced on its web site at http://www.accessdata.fda.gov/scripts/cder/ob/eclink.cfm. 
 1.27 “Orange Book Patents” shall mean any Patents that are listed in the Orange Book. 
 1.28 “Patents” shall mean any and all patent(s) and patent applications Controlled by Chiesi as well as any extension thereof, including supplementary protection certificates,
together with any continuations, continuations-in-part, divisions, reissues and re-examinations thereof, listed in the schedule attached hereto as Appendix A. The Parties shall promptly add to Appendix A any new or additional patents which, if not
licensed herein, would be infringed by having made, importing, storing, handling, using, promoting, distributing, marketing, selling or otherwise transferring physical possession of or otherwise transferring title in or to the Product. Appendix A
shall at all times be deemed to have been updated and amended by the Parties to the extent that such new or additional Patents may from time to time be filed or identified. 
 1.29 “Product” shall mean the product whose specifications appear on Schedule 1.33, and any other product containing the Compound which would, if not licensed under this agreement,
infringe the Patents; Product shall also, as may be appropriate to the context, include any Improvements and any authorized generic formulation of any Product in the event that a third party generic to the branded Product receives approval by an
Agency in the Territory with the same Generic Code Number code. 

  
 4 

 1.30 “Regulatory Authorities” shall mean any Agency which has
responsibility in the Territory for granting Marketing Authorization. 
 1.31 “Regulatory Requirements”
shall mean all applicable standards relating to drug products, as identified in the Act. 
 1.32 “SKU”
shall mean a specific packaged presentation of a defined quantity of a specific dosage strength of the Product, to be identified in the Territory by National Drug Code labeler code specific to Cornerstone or a subsidiary of Cornerstone as the
labeler. 
 1.33 “Specifications” shall mean all finished product specifications, packaging
specifications and stability specifications, pursuant to the Regulatory Requirements and as approved in the Territory under the Marketing Authorization with which compliance is required for the fabrication, packaging, labeling, testing, storage,
handling, sale, release and continued marketing of the Product in the Territory. 
 1.34 The “Supply
Agreement” shall mean the supply agreement with Teva API BV, attached as Exhibit A. 
 1.35
“Term” shall mean the Initial Term and the Extended Term. 
 1.36 “Territory” shall
mean the United States of America and all its territories and possessions throughout the world. 
 1.37 “Third
Party” shall mean any entity other than Chiesi, Cornerstone and their respective Affiliates. 
 1.38
“Trademark” shall mean any trademark, registered to Chiesi by USPTO and approved by FDA for inclusion on the label of the Product. If the selection thereof is made by Cornerstone, then Cornerstone shall, upon reimbursement of
all of its reasonable out of pocket expenses incurred in connection with the selection and registration of such trademark (such amount in no event to exceed $55,000), assign and transfer free of charge all rights, title and interest, if any,
associated thereto to Chiesi prior to filing its affidavit of use of such trademark with the USPTO. The parties will add to Appendix A the trademark to be used as the Trademark. 

1.39 “Valid Claim” shall mean a claim in a granted and unexpired patent or a supplementary protection certificate
included in the Patents which has not been disallowed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, from which no appeal can be or has been taken within the
time period for doing so and which would be infringed by the Product, its manufacture, sale or use thereof and has not been disclaimed, denied or admitted to be invalid or unenforceable through re-issue or disclaimer or otherwise. 

  
 5 

 1.40 Interpretation. Unless the context of this Agreement otherwise requires,
(a) words of one gender include the other gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and
derivative or similar words refer to this entire Agreement; (d) the terms “Article” and “Section” refer to the specified Article and Section of this Agreement; (e) all currencies shall be shown in United States Dollars;
and (f) whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed
by those words or words of like import. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days. The English language shall be controlling in all respects in this Agreement.

 1.41 Additional Definitions. Each of the following definitions is set forth in the Section of this Agreement indicated
below: 
  

			
	 Definition
	  	Section
	
Agreement
	  	Preamble
	 Chiesi
	  	Preamble
	 Chiesi
Intellectual Property
	  	8.1
	 Confidential Information
	  	11.1
	
Cornerstone
	  	Preamble
	 Effective Date
	  	Preamble
	 Extended
Term
	  	12.1
	 Instrument of Authority
	  	5.1
	 Initial
Term
	  	12.1
	 JDC
	  	4.1
	
Parties
	  	Preamble
	 Pharmacovigilance Agreement
	  	4.9
	
Report
	  	6.4
	 Transfer Date
	  	4.12

 ARTICLE 2 
 GRANT 
 2.1 License Grant. Chiesi hereby grants to Cornerstone, and
Cornerstone hereby accepts from Chiesi, a non-transferable, exclusive (even as to Chiesi) license under the Patents, the Know-How and the Trademark, for the purposes of having made, (subject to the terms of this Agreement) and importing the
Compound, and having made, (subject to the terms of this Agreement), storing, handling, using, promoting, distributing, marketing, offering for sale and selling the Product in the Territory for use in the Field of Use. 

2.2 External Opportunities. Cornerstone hereby agrees that, during the term of this Agreement, and unless expressly agreed upon by
the Parties in writing, Cornerstone shall not, directly or indirectly, make, import, store, handle, use, promote, distribute, market, offer for sale or sell the Product outside the Field of Use or outside the Territory. Furthermore, all inquiries or
orders received or known to Cornerstone relating to the (i) sale or delivery of the Product outside the Territory or (ii) use of the Product outside the Field of Use shall be referred by Cornerstone to Chiesi. It is Cornerstone’s
responsibility to document and communicate the specific details of all business opportunities relating to the foregoing to Chiesi. 

  
 6 

 2.3 Sublicensing; Co-Promotion. Cornerstone shall not have the right to grant
sublicenses without the prior written consent of Chiesi, such approval not to be unreasonably held or delayed. In addition, Cornerstone may not enter into any co-promotion agreements concerning the Product for use in the Field of Use for sale in the
Territory without the express written consent of Chiesi as to the co-promoting Party, such approval not to be unreasonably held or delayed. Cornerstone shall in any case be responsible to Chiesi for all acts and omissions of such sub-licensee or
co-promoting Party, if any, as they relate to this Agreement. 
 2.4 Competitive Products. Cornerstone shall not,
directly or indirectly, manufacture, supply, sell, promote, market or distribute, for itself or for the benefit of any Third Party, any Competitive Product within the Territory for the duration of this Agreement. Without prejudice to the foregoing,
should there be an authoritative body of medical opinion supporting the efficacy of using such Competitive Product as an adjunct to or in combination with the Product for the treatment of patients suffering from chronic pulmonary infections, the
Parties shall discuss in good faith how to address such situation. Should Cornerstone breach at any time the above obligation, Chiesi shall be entitled to terminate this Agreement upon a prior written notice of at least thirty (30) Business
Days to Cornerstone. 
 ARTICLE 3 
 OBLIGATIONS OF CORNERSTONE 
 The following obligations of Cornerstone shall
begin upon the Transfer Date: 
 3.1 Own Account. Cornerstone shall place orders for the Product as set forth in Article
5 below and shall resell the ordered Product to Cornerstone’s customers solely in the Field of Use in the Territory. 

3.2 Efforts. Cornerstone shall promote, distribute, market, offer for sale and sell the Product using commercially reasonable
efforts to achieve maximum market impact and concentration throughout the Territory. In addition, Cornerstone shall use commercially reasonable efforts to ensure that the First Commercial Sale in the Territory occurs within nine (9) months
after obtaining both (i) the Marketing Authorization and (ii) approval by FDA of a label for the Product that includes a registered Trademark (which may include a Trademark approved for registration based on intent to use). In the event
Cornerstone fails to make the First Commercial Sale within the above time period, this Agreement shall be automatically and immediately terminated, without any further act, provided, however, that if Cornerstone fails to make the First Commercial
Sale within such nine (9) month period due to (i) non-conformance of the Product to the Specifications, or (ii) inability to secure the Product from Catalent within the above time-period for reasons not attributable to Cornerstone,
then such period shall be suspended for the duration of such circumstance. 
 3.3 Information and Reports. Cornerstone
shall provide Chiesi with written and oral reports, market information, competitive activities, sales forecasts, development of prices 

  
 7 

 
and other pertinent customer and industry information as may be reasonably required from time to time by Chiesi and to keep Chiesi informed of Cornerstone’s activities, consistent with
Cornerstone’s ordinary course of business. In addition, Cornerstone shall keep Chiesi regularly informed of all other material details concerning the promotion, distribution, marketing and sale of the Product in the Territory as Chiesi may
reasonably request. 
 3.4 Facilities. Cornerstone, or its designees, shall maintain facilities in the Territory suitable
for the conduct of Cornerstone’s business, and in compliance with the Regulatory Requirements. Cornerstone agrees that Chiesi may inspect, or have inspected, the facilities of Cornerstone to determine compliance with the Regulatory Requirements
associated with the storage and distribution of the Product. In addition, Chiesi shall have the right, upon reasonable notice and during business hours, to inspect or cause to be inspected at its own expense the facilities of Cornerstone where the
Product is stored. 
 3.5 Records. Cornerstone and its designees, shall maintain accurate records pertaining to the sale
and distribution of the Product to its customers, for a period of at least one year after the expiration date of each lot or batch of such Product, or such longer period as may be required by the Regulatory Requirements, with sufficient detail to
enable the recall of such Product from the market. Cornerstone shall also maintain accurate records of all complaints it has received regarding the Product, and the results of the investigation thereof, for a period of at least one year after the
expiration date of the lot or batch of such Product, or such longer period as may be required by the Regulatory Requirements. 

3.6 Training. Cornerstone shall ensure that the Product is stored in compliance with the Regulatory Requirements, and is shipped
to its customers, under the supervision of personnel having training sufficient to protect the health of the consumer and purchaser. Cornerstone shall train and maintain an adequate staff of appropriate personnel, sufficiently knowledgeable about
the Product and Chiesi training guidelines, in order to enable such personnel to effectively (i) promote the sale of the Product, (ii) respond to customer inquiries and complaints and (iii) respond to inquiries from regulatory
personnel. 
 3.7 Compliance with Laws and Instructions. Cornerstone shall hold all applicable licenses, and shall comply
with all related directives, laws, rules and regulations, in connection with the importation, storage, handling, promotion, distribution, marketing and sale of the Product in the Territory. In its promotion, marketing or sale of the Product,
Cornerstone agrees to avoid making any statements, representations, warranties or guarantees concerning the Product except as expressly authorized pursuant to the Marketing Authorization for the Product. Cornerstone shall, in its importation,
storage, handling, distribution, marketing and sale of the Compound and the Product, comply with the Regulatory Requirements and the reasonable quality standards of Chiesi. 
 3.8 Inventory. Subject to Cornerstone taking an assignment of the Supply Agreement and the Manufacturing Agreement as contemplated by Section 5.1, Cornerstone shall use commercially reasonable
efforts to enforce the terms of the Supply Agreement and the Manufacturing Agreement in order to maintain sufficient stocks of Product to meet all reasonably foreseeable demands for the Product in the Territory without undue delay, and in no event
to maintain less stock than would be necessary to meet three (3) months demand, provided, however, that Cornerstone shall have no obligation to purchase into inventory any Product with less than 18 months shelf life. Cornerstone shall not be
held to the aforementioned standard in the event of inventory shortfall arising from supply issues from the Product supplier(s) and not attributable to Cornerstone. 

  
 8 

 3.9 Selling Costs. For the avoidance of doubt, all importing, storing, handling,
promoting, distributing, marketing and selling costs and expenses relating to the Product within the Territory shall be borne exclusively by Cornerstone. 
 ARTICLE 4 
 PRODUCT DEVELOPMENT, MARKETING AUTHORIZATION AND
PHARMACOVIGILANCE 
 4.1 Joint Development Committee. The Parties shall establish a joint development committee
(“JDC”) that will be responsible for overseeing and facilitating the development of the Product in the Field of Use until approval thereof in the Territory. The JDC shall have solely the powers expressly assigned to it
in this Article 4 and shall not have any power to amend, modify, or waive compliance with this Agreement. 
 4.1.1
Membership. The JDC will consist of three (3) senior representatives from each Party, or such other number that the Parties may agree upon in due course, each of whom will have sufficient seniority within the applicable Party to make
decisions arising within the scope of the JDC’s responsibilities. Cornerstone and Chiesi will each designate a co-chair for the JDC. 
 4.1.2 Meetings. The JDC will meet at such frequency as shall be established by the Parties (but not less frequently than three (3) times per year). Meetings of the JDC shall alternate
between the offices of the Parties, unless otherwise agreed upon by the members of the JDC, or may be held telephonically or by video conference; provided, however, that at least one (1) meeting per year shall be a face to face meeting.
Meetings of the JDC shall be effective only if at least two (2) representatives of each Party are in attendance or participating in the meeting. Members of the JDC shall have the right to participate in and vote at meetings by telephone. Each
Party shall be responsible for expenses incurred by its employees and its members of the JDC in attending or otherwise participating in JDC meetings. The initial JDC meeting will be arranged by both Parties as soon as possible after the Effective
Date. 
 4.1.3 Decisions. Each Party’s representatives on the JDC will collectively have one vote on all
matters that are within the responsibility of the JDC. The JDC members will use reasonable efforts to reach consensus on all decisions. In the event of a deadlock regarding a particular issue on which the members of the JDC cannot reach consensus,
such issue will be resolved as provided in Section 4.1.4. 
 4.1.4 Dispute Resolution. In the event that the
members of the JDC are unable to agree on a particular issue within the responsibility of the JDC, such issue shall be referred to the Chief Executive Officer of Cornerstone and the Chief Executive Officer of Chiesi for attempted resolution of such
matter. Such officers shall use good faith efforts to resolve promptly such matter, which good faith efforts shall include at least one teleconference between 

  
 9 

 
such officers within twenty (20) days after the submission of such matter to them. In the event that such officers are unable to reach consensus with respect to a particular issue after a
period of thirty (30) days from its submission through good faith negotiations, then Chiesi shall have the final authority to resolve such issue. 
 4.1.5 Discontinuation of the JDC. The JDC shall continue to exist until the first to occur of (a) the Parties mutually agree to disband the JDC, and (b) obtaining of the Marketing
Authorization, at which time the responsibilities of the JDC as set out in Section 4.1 shall be taken over by Cornerstone, at its own expense. 
 4.2 Transfer of Marketing Authorization. Upon issuance of the Marketing Authorization, Chiesi shall instruct its counsel to effect the transfer thereof to Cornerstone no later than thirty
(30) days after such issuance (the “Transfer Date”). All expenses related to the transfer shall be borne by Cornerstone. Furthermore, Chiesi will make available to Cornerstone, copies of any and all Product regulatory data
(including manufacturing, clinical and/or preclinical data) filed in the Territory. 
 4.3 Maintenance. Upon the Transfer
Date, Cornerstone shall be fully responsible for, at its own expense, taking such steps and actions, consistent with its legal and regulatory obligations and its commitments under this Agreement, as may be necessary and advisable to maintain the
Marketing Authorization held by Cornerstone in the Territory, including making all applications, requests for authorizations and submissions of information related to the Marketing Authorization Application, and including sole responsibility for the
payment and organization of any post-Marketing Authorization study. 
 4.4 Conditional Marketing Authorization. In the
event the Marketing Authorization is granted with a label that is materially different from that submitted with the NDA, Cornerstone shall have the right to terminate this Agreement pursuant to Section 12.2. Without prejudice to the foregoing,
in the event the Marketing Authorization is granted subject to the conduct of any study, and Cornerstone is willing and able to conduct such study, such study(ies) shall be conducted at an equally shared cost between Cornerstone and Chiesi. With
respect to any post Marketing Authorization study to be conducted pursuant to this section 4.4, Cornerstone shall have no obligation to conduct and fund such study, and the Parties shall reassess their respective commitments in this regard, if the
cost to Cornerstone of such activities would exceed $1,000,000. 
 4.5 Protocols. Prior to the commencement of any
external scientific investigation, Cornerstone shall provide Chiesi, for Chiesi’s approval, with a protocol, including the relevant clinical report form, for any study to be undertaken by Cornerstone with the Product. Chiesi shall have the
right to disagree with or request a modification of such proposed study, in particular whether it might reasonably be deemed harmful for the sound international development of the Product. Chiesi shall reply in writing no later than twenty
(20) Business Days from the receipt of the protocols in question, otherwise the protocols will be deemed accepted by Chiesi. 

  
 10 

 4.6 Reports/Studies. 

4.6.1 Study Reports. Cornerstone undertakes to keep Chiesi duly and fully informed of the efforts made by Cornerstone
pursuant to Section 4.4, by providing Chiesi upon request, but no less frequent than every six (6) months, with detailed reports in writing informing Chiesi of the progress made and results of the studies performed with the Product in the
Territory. 
 4.6.2 Cornerstone Study Results. Cornerstone shall make available to Chiesi, as soon as possible,
results of all studies made with the Product to the extent Cornerstone has Control of such results. Chiesi shall be free to use, directly or indirectly, all such results in and outside the Territory free of charge. 

4.6.3 Chiesi Study Results. Chiesi shall make available to Cornerstone, as soon as possible, results of all studies made
with the Product to the extent Chiesi has Control of such results. Cornerstone shall be free to use, directly or indirectly, all such results in the Territory pursuant and subject to the terms of this Agreement. 

4.6.4 Regulatory Status. Furthermore, Cornerstone shall keep Chiesi informed of the status of IND(s), Marketing
Authorization Application(s), Marketing Authorization and other authorizations held or managed by Cornerstone pursuant to Section 4.3, by providing Chiesi with documents and reports in the following manner: 

(a) with respect to IND(s) or Marketing Authorization Application(s) or Marketing Authorization, Cornerstone shall regularly, and
in any case within twenty (20) Business Days, inform Chiesi of any submissions or grants thereof by sending Chiesi a written report by the most appropriate means of transmission; and 

(b) with respect to any and all filings, authorizations, acceptances, permissions, material correspondence or similar relevant
documents, Cornerstone shall provide Chiesi with copies, by the most appropriate means of transmission, regularly upon dispatch or receipt thereof and in any case within forty (40) Business Days. 

4.7 New Development Plans. Cornerstone shall have the right to propose any new development plan for the Product in the Territory
for Chiesi’s evaluation, it being understood and agreed that Chiesi shall have no obligation whatsoever to approve such plan(s). 
 4.8 Meetings. The Parties shall meet at least twice a year in person, unless otherwise mutually agreed by the Parties, to share, discuss and evaluate medical, scientific, commercial, legal, quality
and regulatory information relevant to the Product. 
 4.9 Pharmacovigilance. The Parties agree that, upon execution of
this Agreement, and in no event later than ten (10) weeks after the Effective Date, they shall either amend the existing Pharmacovigilance agreement between the Parties or enter into a separate Pharmacovigilance agreement, containing all
customary terms and conditions, for the exchange of adverse event and safety information, including pregnancy exposure data concerning the Product (the “Pharmacovigilance Agreement”). Until the Pharmacovigilance Agreement is
finalized, the Parties shall exchange such data in a manner that enables each Party to fulfill regulatory requirements within their own territories (and within any other limits of this Agreement). 

  
 11 

 ARTICLE 5 
 SUPPLY AND MANUFACTURING 
 5.1 Responsibility for Supply and
Manufacturing. Pursuant to Section 2.1, Chiesi shall, within ten (10) days after the Effective Date, and as a condition subsequent to the effectiveness of this Agreement (which, if not fulfilled, shall void this Agreement),
(i) execute such documents (each an “Instrument of Authority”) and take such actions as may be necessary to assign and transfer to Cornerstone all rights and obligations under the Supply Agreement to enable Cornerstone to directly
purchase the Compound for import thereof in the Territory for the sole purpose set forth in the following paragraph (ii) and (ii) execute such documents (each an “Instrument of Authority”) and take such actions as may be
necessary to assign and transfer to Cornerstone all rights and obligations under the Manufacturing Agreement to enable Cornerstone to have the Product manufactured and directly supplied to Cornerstone by using the Compound purchased in accordance
with the preceding paragraph (i). Consequently, Cornerstone will purchase both the Compound and the Product exclusively from the foregoing suppliers, or any other supplier previously approved in writing by Chiesi, and Cornerstone will entirely
assume the relevant responsibilities arising therefrom with respect to the Territory. Without prejudice to the foregoing, the above Instruments of Authority will all include a provision to the effect that if this Agreement expires or is terminated
for any reason, the Supply Agreement and Manufacturing Agreement will be deemed to have been assigned by Cornerstone back to Chiesi, automatically and without any action on the part of Chiesi, Cornerstone or any party to such agreements, and that
Chiesi will be solely responsible for liabilities arising under such agreements from and after the effective date of expiration or termination of this Agreement, other than in the event of termination of this Agreement by Chiesi pursuant to Sections
2.4, 8.6.2 or 12.5 or in the event of termination pursuant to Section 3.2. 
 5.2 Records. Cornerstone shall, or
shall require its contract manufacturers to, maintain accurate books and records pertaining to the manufacture and release of the Compound and the Products, as required by the Regulatory Requirements, including all of the manufacturing and
analytical records, all records of shipments of Compound and Products, and all data relating to Compound and Products and complaints Cornerstone has received therefor, for the time periods required by the Regulatory Requirements. Cornerstone agrees
that, in response to any complaint, or in the defense by Chiesi of any litigation, hearing, regulatory proceeding or investigation relating to Compound and Products, Cornerstone shall make available to Chiesi such Cornerstone employees and records
reasonably necessary to permit the effective response to, defense of, or investigation of such matters, subject to appropriate confidentiality protections. 
 5.3 Notification. Cornerstone shall provide Chiesi with written notice as soon as practicable of all claims and allegations, of which Cornerstone becomes aware, that Cornerstone, or its contract
manufacturers, are not complying with the Regulatory Requirements associated with the manufacture or release of Compound and Products for or in the Territory, or that the Products do not comply with the Specifications therefor, which claims or
allegations Cornerstone reasonably believes to warrant investigation or response. 

  
 12 

 5.4 Recalls. In the event (i) any Agency issues a directive, order or, following
the issuance of a safety warning or alert with respect to a product, a written request that any Product be recalled, (ii) a court of competent jurisdiction orders such a recall, or (iii) Cornerstone determines that any Product should be
recalled or that a “dear doctor” letter is required relating to the restrictions on the use of the Product, Chiesi will co-operate, at Cornerstone’s expense, with those activities relating to the Product as reasonably required by
Cornerstone, having regard to all Applicable Laws. Notwithstanding the foregoing, in the event of a recall of the Product, Cornerstone will notify Chiesi in accordance with the Pharmacovigilance Agreement and in any event before initiation of any
such recall, and Chiesi will cooperate, at Cornerstone’s expense, with those recall activities relating to the Product as reasonably required by Cornerstone, after discussion in good faith with Chiesi. 

5.4.1 Cornerstone or its designated agent shall have the responsibility for handling customer returns of the Product. Chiesi shall
provide Cornerstone or its designated agent with such assistance, at Cornerstone’s expense, as Cornerstone may reasonably require to handle such Product returns. 
 5.4.2 For the purpose of clarity, Cornerstone shall be fully and solely responsible for all costs and expenses related to any Product recall or return in the Territory. 

5.4.3 Cornerstone or its designated agent shall have the full responsibility for responding to questions and complaints from
Cornerstone’s customers for the Product. Responsibilities and activities relating to complaints and questions are defined in the Pharmacovigilance Agreement. All costs incurred in respect of this Section 5.4.3 shall be borne by
Cornerstone, subject to any applicable indemnity provisions contained in this Agreement or the Pharmacovigilance Agreement. 

ARTICLE 6 
 FINANCIAL PROVISIONS 
 6.1 Upfront Fee. Within ten (10) days
after the Effective Date, as consideration for the rights granted to Cornerstone pursuant to Section 2.1, Cornerstone shall pay to Chiesi a non-refundable and non-creditable amount of One Million U.S. Dollars ($1,000,000) in cash after receipt
of a proper invoice. 
 6.2 Regulatory Milestone. As further consideration for the rights granted to Cornerstone pursuant
to Section 2.1, Cornerstone shall pay to Chiesi a non-refundable and non-creditable amount of Two Million Five Hundred Thousand U.S. Dollars ($2,500,000) in cash within thirty (30) days after the First Commercial Sale. 

6.3 Royalties. As further consideration for the rights granted to Cornerstone pursuant to Section 2.1, including, in
particular, for the right of having the Product made pursuant to Section 5.1, Cornerstone shall pay to Chiesi royalties on annual Net Sales of the Product in the Territory at the rate of thirty percent (30%) during the Initial Term
(hereinafter defined), it being understood and agreed that such royalties shall be reduced to fifteen percent (15%) on annual Net Sales during the Extended Term (hereinafter defined). 

  
 13 

 6.4 Reports and Royalty Payments. Within thirty (30) days after the end of each
Calendar Quarter, Cornerstone shall deliver a report to Chiesi (a “Report”) specifying, for such Calendar Quarter in the Territory: 
 6.4.1 the quantities of each SKU of Product sold by Cornerstone in that Calendar Quarter; 
 6.4.2 gross sales and the calculation of Net Sales of Product by SKU in the Territory during such Calendar Quarter; 
 6.4.3 all quantities of Product distributed free of charge, together with any documents evidencing such use; 
 6.4.4 the Net Sales Price for each SKU of Product sold in that Calendar Quarter in the Territory; 
 6.4.5 the total royalty amount payable to Chiesi for all SKUs of the Product delivered during such Calendar Quarter calculated in accordance with Section 6.3 using the Net Sales Price for each SKU in
the Territory for the just-ended Calendar Quarter. 
 6.4.6 Simultaneously with the delivery of such Report, Cornerstone shall
transfer, by wire in USD, the due amount of royalties to Chiesi’s bank account indicated from time to time. 
 6.5
Records.  
 6.5.1 Audit. Cornerstone shall keep and maintain true and complete records setting forth
the gross sales of the Product in the Territory, and of all matters relating to the computation of the Net Sales of the Product in the Territory, including quantities of Product used as clinical supplies or in patient assistance programs, volume of
Product distributed, or records otherwise related to Cornerstone’s performance of its obligations under this Agreement, for a period of three (3) years following such sales, such records shall be open to inspection at Cornerstone’s
corporate headquarters on thirty (30) days written notice provided by Chiesi, during the normal office hours of Cornerstone (but not more frequently than once per year) by a nationally recognized independent certified public accountant selected
by Chiesi and reasonably acceptable to Cornerstone, and retained solely for the purpose of auditing the same at Chiesi’s expense; provided, however, that records with respect to any Calendar Quarter may be audited no more than once in
connection with the same audit and/or subject matter; provided, further that nothing in this Section 6.5.1 shall limit Chiesi’s right to have audited Cornerstone’s records with respect to any Calendar Quarter in connection with
Chiesi’s year-end review. Such audit shall be conducted exclusively for the purpose of verifying the accuracy of reports delivered by Cornerstone to Chiesi pursuant to Section 6.4 and the accuracy of Cornerstone’s determination of the
amounts payable or paid by Cornerstone to Chiesi hereunder. The accountant shall sign a confidentiality agreement prepared by Cornerstone and shall then have the right to examine the records kept pursuant to this Section 6.5.1 and report to
Chiesi the findings (but not the underlying data) of such examination of records. The accountant shall provide a draft copy of the report to Chiesi and Cornerstone for review and comment, and each of Chiesi and

  
 14 

 
Cornerstone shall have thirty (30) days after receipt of that report to review and comment on the report which comments shall be provided to the accountant and to each other. The final
report shall be provided simultaneously to Chiesi and Cornerstone by the independent certified public accountant within twenty (20) days after the accountant’s receipt and consideration of such comments. In the event that an audit has been
initiated by Chiesi, the records that have been the subject of the audit shall be kept until the later of (i) the expiry of any time period set out in Section 6.5.2 for the payment or credit of any amounts owing or (ii) the resolution
of any dispute arising from the audit. If such examination of records reveals more than a five percent (5%) underpayment of any amounts payable hereunder as compared to the amounts actually reported by Cornerstone as payable to Chiesi, as
determined by such examination for the period which is the subject of such examination, the expenses for said accountant shall be borne by Cornerstone. 
 6.5.2 Adjustments. Cornerstone shall pay to Chiesi within forty-five (45) days after the delivery of the accountant’s report pursuant to Section 6.5.1 any amounts determined
by the accountant to be payable by Cornerstone to Chiesi. If the accountant determines that Cornerstone has overpaid Chiesi, Chiesi shall pay to Cornerstone within forty-five (45) days after the delivery of the accountant’s report pursuant
to Section 6.5.1 an amount equal to such overpayment. 
 6.6 Withholding Taxes. Chiesi and Cornerstone agree that
all payments due to Chiesi from Cornerstone hereunder shall be made by Cornerstone free and clear of, and without deduction for, any Income or Withholding Taxes, except as otherwise provided in this Section 6.6. If the fiscal or taxing
authorities of any relevant jurisdiction assert that Income or Withholding Taxes are required to be withheld from any payments due to Chiesi or its Affiliates from Cornerstone or its Affiliates, or the tax laws (including statutes, regulations,
treaties and judicial or official interpretations of any of the foregoing) in one or more jurisdictions have changed so as to require such treatment, then (i) the Party made aware of such assertion or change in law shall inform the other Party
within thirty (30) days and shall consult with the other Party regarding the consequences of such assertion or change and (ii) until the conclusion of such consultation Cornerstone and its Affiliates shall be entitled to deduct and
withhold the applicable Income or Withholding Tax from any applicable payments due to Chiesi or its Affiliates and pay such Income or Withholding Tax over to the applicable fiscal or taxing authority. If, after consultation with Chiesi, Cornerstone
believes that it or any of its Affiliates is required to withhold Income or Withholding Tax from any payment to or for the account of Chiesi or its Affiliates, such amount shall be deducted from the amounts payable to or for the account of Chiesi or
its Affiliates and shall be paid by Cornerstone to the appropriate fiscal or tax authorities, provided that Cornerstone shall however take all reasonable steps in order to allow Chiesi to take advantage of the relevant double taxation treaty(ies)
for the purpose of minimizing withholding taxes on such amounts, so long as Chiesi and its Affiliates promptly provides any forms, certificates or other documentation or information that Chiesi or its Affiliates are required or reasonably requested
by Cornerstone to provide in connection with such minimization. Cornerstone shall promptly furnish Chiesi with copies of official tax receipts or other appropriate evidence to support a claim for tax or other credit in respect of any sum so
withheld, and shall provide such assistance as Chiesi may reasonably require in obtaining any refund of such amounts to which Chiesi or its Affiliates may be entitled, to the extent that such assistance does not cause Cornerstone or its Affiliates
to incur any liability in respect of any of the taxes asserted to be due or other cost or expense. For purposes of this Agreement, “Income or Withholding 

  
 15 

 
Tax” means (i) any tax, levy or charge imposed by a governmental authority that is computed or determined by reference to gross or net receipts, revenues, sales, income, earnings,
profits or gains of Chiesi or any of its Affiliates or any office, branch, permanent establishment or trade or business of Chiesi or any of its Affiliates, (ii) any tax, levy or charge imposed by a governmental authority as a result of the
payment or accrual of amounts to or for the account of Chiesi or any of its Affiliates in respect of the grant of rights or sale of Product by Chiesi or any of its Affiliates to Cornerstone or any of its Affiliates pursuant to this Agreement, and
(iii) any additional amount, penalty, interest or addition to tax imposed with respect to the foregoing or cost or expense relating to the imposition or contest of the foregoing. 

6.7 Third Party Pricing. Without prejudice to Chiesi’s rights under Section 7.1, nothing contained herein, however,
shall be deemed to limit in any way Cornerstone’s right to determine the prices at which the Products purchased by Cornerstone may be sold by Cornerstone to any Third Party. 

ARTICLE 7 
 MARKETING OF THE PRODUCT 
 7.1 Marketing Plan. No later than two
(2) months before the Transfer Date, Cornerstone shall provide Chiesi with its proposed marketing plan for the Product, based on Chiesi’s template, during the first year of this Agreement, and thereafter shall provide Chiesi with its
proposed marketing plan no later than three (3) months before the second and subsequent years, as the case may be. Such proposed marketing plans shall be duly carried out by Cornerstone, taking into account all comments and suggestions of
Chiesi. Furthermore, within fifteen (15) Business Days of the end of each Calendar Quarter, Cornerstone shall send Chiesi a written report detailing advertising and promotional activities carried out in the said quarter. 

7.2 Chiesi Approval of Marketing Materials. Cornerstone shall submit to Chiesi for Chiesi’s prior written approval, copies of
all marketing and promotional materials and copies of all other printed materials which Cornerstone proposes at any time to use in relation to the promotion, marketing, sale or offer for sale of the Product. If Chiesi fails to respond to a request
to approve any promotional or marketing material within fifteen (15) Business Days after receipt of Cornerstone’s submission by Chiesi, such failure shall constitute approval of the submission. 

7.3 Compliance with Marketing Authorization. All promotional and sales material, including advertisement, sales and training aids,
if locally prepared and used by Cornerstone with respect to the Product, shall fully comply with Applicable Laws and with the Marketing Authorization in the Territory. In addition, Cornerstone will seek final approval from Chiesi in writing (such
approval not to be unreasonably withheld) before distributing such promotional and sales material. If Chiesi fails to comment on such material within fifteen (15) Business Days upon receipt thereof, then such material shall be considered
approved by Chiesi. Furthermore, all promotional and sales material contemplated by this Section, along with all inner and outer packaging items of the Product, shall clearly indicate the legend “Under license of CHIESI”. 

7.4 Prevailing Market Conditions. Cornerstone agrees to keep Chiesi reasonably and promptly informed of all relevant market
conditions prevailing within the Territory, which includes providing Chiesi with information regarding development of prices, competing products and relevant legal regulations. 

  
 16 

 ARTICLE 8 
 INTELLECTUAL PROPERTY 
 8.1 Ownership of Intellectual Property.
Chiesi or its Affiliates or licensors shall remain the owner of the intellectual property relating to the Products including any and all rights to any scientific, pharmaceutical or technical information, data, discovery, invention (whether
patentable or not), Know-How, substances, techniques, processes, systems, formulations, designs and expertise relating to the Product which is not generally known to the public and any and all rights under any and all Patents and the Trademark
(collectively, the “Chiesi Intellectual Property”). 
 8.2 Improvements. 

8.2.1 Chiesi’s Improvements. Chiesi shall promptly notify Cornerstone of any Improvements Controlled by Chiesi and
such Improvement shall be included in the license granted pursuant to this Agreement for the benefit of Cornerstone and consequently such Improvement shall be considered a Product hereunder. 

8.2.2 Cornerstone’s Improvements Cornerstone shall promptly notify Chiesi of any Improvements Controlled by
Cornerstone. Any such Improvements, whether patentable or not, shall be the sole property of Chiesi, regardless of inventorship. Subject to Section 8.2.1, Cornerstone shall assign, with no more than nominal consideration and shall ensure that
any of its employees, agents and officers who are inventors of Improvements assign, to Chiesi, and hereby does assign, all rights to such Improvements at no cost to Chiesi, and such Improvement shall be included in the license granted pursuant to
this Agreement for the benefit of Cornerstone and consequently such Improvement shall be considered a Product hereunder. Cornerstone shall provide Chiesi with reasonable support in the filing and prosecution of any patent applications for
Improvements and shall provide all information and/or data in Cornerstone’s possession that is necessary to support any such patent application. 
 8.3 Prosecution and Maintenance Chiesi shall diligently pursue the approval and registration of the Trademark at its own expense. Chiesi shall also diligently prosecute all pending patent
applications and maintain all Patents relating to the Product or any Improvement and pending in the Territory, including all applications that may in future be filed as a result of Improvements. Chiesi shall provide Cornerstone with the opportunity
to consult and comment upon material prosecution decisions with respect to the Patents in the Territory. Notwithstanding the foregoing, Chiesi shall have the right to decline to prosecute (or in the case of an application relating to a future
Improvement, decline to file) an application, provided, however, that in the event that Chiesi elects not to pursue any such prosecution, it shall promptly so notify Cornerstone and provide to Cornerstone the opportunity and necessary support to
enable Cornerstone to pursue such prosecution(s) at Cornerstone’s own cost and expense, it being however understood and agreed that Cornerstone shall not be obliged to so pursue. Chiesi shall promptly file in the Orange Book any Patent that is
issued and qualifies for inclusion in the Orange Book. 

  
 17 

 8.4 Defense In the event of any claim, threat, potential threat, or suit by a Third
Party against either Cornerstone or Chiesi alleging infringement by the Product of any patents or other Intellectual Property Rights of such Third Party, the Party receiving such notice shall promptly notify the other Party in writing of such fact,
and Chiesi shall use its reasonable efforts to defend such suit, and to the extent it incurs expenses in connection with such defense, it shall bear such expenses. 
 8.4.1 Cornerstone shall reasonably support the efforts of defending against a claim, threat, potential threat or suit, and to the extent it incurs expenses in connection with providing such
support, it shall bear such expenses. 
 8.4.2 In the event that as a result of the resolution or approved settlement of
any suit, or any anticipatory arrangement entered into in order to avoid the threat or potential threat of a suit, arising under this section Cornerstone is obliged to remit payments (including license and/or royalty payments) to a Third Party in
relation to Third Party intellectual property that would be infringed (or prospectively be infringed) by the commercialization of the Product in the Territory, Cornerstone shall be permitted to offset up to fifty percent (50%) of such payments
due to such Third Party against the royalties otherwise owed by Cornerstone to Chiesi; provided however, to the extent that 50% of such payments may in any calendar year exceed the amount of royalties that would otherwise be payable to Chiesi during
such calendar year, the amount of such excess shall be carried over to future years and may be offset against royalties that would otherwise be payable to Chiesi in such future years. 

8.4.3 Notwithstanding the foregoing, if an alleged infringement relates to Cornerstone’s corporate logo or any other
Cornerstone-owned trade dress the Parties agree to include on the packages, labeling and inserts related to the Product, then all costs related to the defense of such allegation shall be borne by Cornerstone. 

8.5 Enforcement. 
 8.5.1 Cornerstone shall promptly inform Chiesi in writing of any actual or alleged unauthorized use or infringement of the Chiesi Intellectual Property by a Third Party of which it becomes aware
and provide Chiesi with any available evidence of such unauthorized use. Cornerstone shall have the first right, but not the obligation, to conduct all enforcement proceedings relating to Chiesi Intellectual Property, at it own cost and expense,
provided that Chiesi shall have the right to join any such proceedings. If Cornerstone successfully enforces the Chiesi Intellectual Property Rights, it shall first have the right to recoup one hundred percent (100%) of its out of pocket
expenses incurred from any recovery, and Chiesi shall then recover one hundred percent (100%) of any costs incurred, and any remaining proceeds (including damages, settlement proceeds or sublicense proceeds) shall be paid seventy percent
(70%) to Cornerstone, and thirty percent (30%) to Chiesi, it being however understood and agreed that in the event Cornerstone and Chiesi enforce the Chiesi Intellectual Property Rights jointly, then the above remaining proceeds shall be
split 50/50. 
 8.5.2 If Cornerstone elects not to exercise its right pursuant to Section 8.3.1.within a reasonable
amount of time, Cornerstone shall promptly notify Chiesi in writing of its election, and of the circumstance of such infringement. In such event Chiesi shall have the 

  
 18 

 
right, but not the obligation, to conduct all enforcement proceedings relating to Chiesi Intellectual Property, at its own cost and expense, provided that Cornerstone shall have the right to join
any such proceedings. If Chiesi successfully enforces the Chiesi Intellectual Property Rights, it shall first have the right to recoup one hundred percent (100%) of its out of pocket expenses incurred from any recovery, and Cornerstone shall
then recover one hundred percent (100%) of any costs incurred, and any remaining proceeds (including damages, settlement proceeds or sublicense proceeds) shall be paid seventy percent (70%) to Chiesi, and thirty percent (30%) to
Cornerstone, it being however understood and agreed that in the event Chiesi and Cornerstone enforce the Chiesi Intellectual Property Rights jointly, then the above remaining proceeds shall be split 50/50. 

8.5.3 No settlement or consent judgment or other voluntary final disposition of a suit, or a threatened or potential suit, under
this Article 8 may be entered into by either Party without the prior written consent of the other Party, such consent not to be unreasonably withheld. Either Party shall reasonably cooperate with, and support, at it own cost and expense, the other
Party and either Party shall execute or cause the execution of such legal papers in connection with the foregoing as may be reasonably requested by the other Party. 
 8.6 Chiesi Intellectual Property. 
 8.6.1 Cornerstone shall only
market and sell the Product in the Field of Use in the Territory under the Trademark. 
 8.6.2 Cornerstone acknowledges
that Chiesi or its Affiliate or licensors are the owner of all rights, title and interest to the Patents, the Trademark and all associated goodwill, and any act that diminishes the value of such ownership interest may be treated as a material breach
of this Agreement, provided, however, that Cornerstone further acknowledges that if such act is willful, or if Cornerstone challenges the validity, scope or enforceability of the Patents and/or the Trademark, or the substantial and secret nature of
the Know-How in the Territory, then the process provided in section 12.5 shall not apply and Chiesi may terminate this Agreement with immediate effect. For the avoidance of doubt, Chiesi shall not have any rights with respect to
Cornerstone’s logo and any other Cornerstone-owned trade dress the Parties agree to include on the packages, labeling and inserts related to the Product. 
 8.6.3 Cornerstone will not attack, dispute, or contest the validity or the ownership of the Patents and the Trademark or any registrations issued or issuing with respect thereto, both during the
Term of this Agreement and thereafter. Cornerstone’s use of the Trademark shall inure to the benefit of Chiesi, for all purposes including trademark registrations. In the event Cornerstone acquires any rights relating to the Patents and/or the
Trademark for any reason, Cornerstone agrees to assign, and hereby does assign, at no cost, all such rights, together with any related goodwill, to Chiesi. Cornerstone shall use its best efforts not to do any act which would or might endanger,
destroy or similarly affect the value of the goodwill pertaining to the Trademark nor do any act which might support a petition to cancel any registration relating to the Trademark or cause the applicable registrar to require a disclaimer of
exclusive rights in such Trademark nor assist any other person or other entity directly or indirectly in such act. Cornerstone will immediately execute any documents presented to it by Chiesi to confirm Chiesi’s ownership of all such rights.

  
 19 

 8.6.4 Cornerstone shall ensure that each reference to and use of the Trademark by
Cornerstone is in a manner approved by Chiesi and accompanied by the acknowledgement as follows: “[Trademark] is a registered trademark of Chiesi Farmaceutici S.p.A.” 

8.6.5 Cornerstone shall comply with all reasonable instructions issued by Chiesi relating to the form and manner in which the
Trademark shall be used in connection with the marketing of the Product by Cornerstone and to discontinue, upon notice from Chiesi, any practice relating to the use of the Trademark which in Chiesi’s reasonable opinion would adversely affect
the rights or interest of Chiesi in such Trademarks. Cornerstone shall not alter the packaging of the Products or conceal, obscure, remove or otherwise interfere with the Trademark or other markings including an indication of the source of origin
which may be placed on the Product for Chiesi. Cornerstone shall ensure that the Product is promoted, distributed, handled, marketed, stored on its (or its designee’s) premises, and shipped to its customers, in such a manner that would not
depreciate the goodwill associated with the Trademark used in association with the Product. 
 8.6.6 In the event that a
conflict arises between the interests of Chiesi and Cornerstone in any litigation described in this Article 8, the Party that is not funding the litigation shall have the right to be represented by counsel of its own choice and at its sole expense.

 8.6.7 Cornerstone shall not sell, market, distribute or use for any purpose any Product or marketing, packaging or
labeling materials related to the Product which are damaged, defective or otherwise fail to meet the specification or quality standards or the trademark usage requirements of this Agreement. Furthermore, during the Initial Term (including the
possible Extended Term), and after its termination for any reason whatsoever, Cornerstone shall not use any trademark or trade name identical with or confusingly similar to the Trademark and shall not apply, before any authority of any country, for
the registration of any internet domain name (nor any other creative expression that may be the subject of registration), containing, in any form or graphic character, the name “Chiesi” and/or the Trademark used hereunder (and/or any other
denomination confusingly similar to the aforesaid names). 
 8.7 No Other Rights. Other than the rights expressly granted
under this Agreement, Cornerstone shall not acquire any rights to or under any Chiesi Intellectual Property. Except as set forth herein and therein, Cornerstone shall have no right to use the trade names, trademarks or other intellectual property of
Chiesi except as provided in writing in advance by Chiesi. Upon termination of this Agreement, Cornerstone will discontinue all use of the Chiesi name, Trademark and the Chiesi Intellectual Property and discontinue all representation that it is or
was an authorized representative of Chiesi. This Section 8.7 shall survive the expiration or termination of this Agreement.  
 ARTICLE 9 
 REPRESENTATIONS, WARRANTIES AND COVENANTS 

9.1 Mutual Representations, Warranties and Covenants. Each Party represents, warrants and covenants that: 

  
 20 

 9.1.1 it is a corporation duly organized, validly existing and in good standing under
the laws of its jurisdiction of incorporation and has the corporate power and authority to execute, deliver, and perform this Agreement; 
 9.1.2 the execution of this Agreement and the performance thereof have been duly authorized by all necessary corporate action on its part and do not conflict with the terms or conditions of any
agreement to which such Party is subject; 
 9.1.3 when executed and delivered by it, this Agreement will constitute a
legal, valid and binding obligation of it, enforceable against it in accordance with the provisions of this Agreement; and 

9.1.4 it shall perform its obligations under this Agreement in compliance with all Applicable Laws. 

9.2 Additional Representations, Warranties and Covenants of Cornerstone. 

9.2.1 Cornerstone represents, warrants and covenants that: (a) it has duly investigated the Know-How and the Patents in order
to determine its interest in entering into this Agreement; (b) it shall represent the Product accurately and fairly and shall refrain from misleading or unethical business practices; (c) it shall conduct its business in a manner that
reflects favorably on the Product and the good name, goodwill and reputation of Chiesi; (d) it shall avoid deceptive or unethical practices, including disparagement of the Product and (e) it shall not make any representations, warranties
or guarantees to customers or other Third Parties or to the trade with respect to the Specifications, features or capabilities of the Product that are inconsistent with the literature or documentation provided by Chiesi. 

9.2.2 To its knowledge, Cornerstone (i) is not debarred, (ii) is not in the process of being debarred, (iii) has
not been threatened with debarment and (iii) does not use the services of any persons who have been, or are in the process of being, debarred under 21 U.S.C. § 335a(a) of the Act or any comparable law. Furthermore, neither Cornerstone nor,
to its knowledge, any of its officers, employees, or consultants has been convicted of an offense under (i) either a federal or state law that is cited in 21 U.S.C. § 335(a) as a ground for debarment, denial of approval, or suspension, or
(ii) any other law cited in any comparable Applicable Law as a ground for debarment, denial of approval or suspension. 

9.2.3 Cornerstone has all Agency consents necessary or desirable in performance of its obligations hereunder and the commercial
sale of the Product in the Territory. 
 9.2.4 Cornerstone will not market the Product outside the Field of Use or
outside the Territory nor will it sell the Product to any Third Party for sale or distribution outside the Field of Use or outside the Territory. 
 9.2.5 All Product commercialized by Cornerstone, or under its authority, shall (i) be made, imported, stored, handled, used, promoted, distributed, marketed, offered for sale and sold in
compliance with the terms of this Agreement, the Act and all Applicable Laws; (ii) be in accordance with and conform to any applicable standards specified by the United States Pharmacopeia and Pharmacopeia Forum and the European Pharmacopeia
and Pharmacopeial Forum and (iii) be free from any material that would cause the Product to be adulterated or misbranded within the meaning of the Act. 

  
 21 

 9.3 Additional Representations, Warranties and Covenants of Chiesi. 

9.3.1 Chiesi represents, warrants and covenants that, to its knowledge, the purchase, sale, use, disposition, and advertisement of
any Product or the Trademark by Cornerstone will not infringe on or violate any patent, design, copyright, trademark, trade secret, or other right of any Third Party, provided that said activities are not performed in contravention of this
Agreement. Chiesi has no knowledge of any pending or potential claim or action alleging any such infringement. Chiesi has the right to grant the rights to Cornerstone contemplated in this Agreement in the Territory. 

9.3.2 Neither Chiesi nor, to its knowledge, any of its officers, employees, or consultants has been convicted of an offense under
(i) either a federal or state law that is cited in 21 U.S.C. § 335(a) as a ground for debarment, denial of approval, or suspension, or (ii) any other law cited in any comparable Applicable Law as a ground for debarment, denial of
approval or suspension. 
 9.3.3 Chiesi and its Affiliates will not market the Product in the Field of Use in the
Territory nor will they sell the Product to any Third Party for sale or distribution in the Field of Use in the Territory. 

9.3.4 Exhibit A is a true and correct copy of the Supply Agreement, together with an Instrument of Authority as set forth in
Section 5.1. Such Supply Agreement is in full force and effect. The execution of the Instrument of Authority will not in any way limit the full force and effect of such Supply Agreement. 

9.3.5 Exhibit B is a true and correct copy of the Manufacturing Agreement, together with an Instrument of Authority as set forth
in Section 5.1. Such Manufacturing Agreement is in full force and effect. The execution of the Instrument of Authority will not in any way limit the full force and effect of such Manufacturing Agreement. 

9.4 Disclaimer. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, ALL WARRANTIES, CONDITIONS, AND REPRESENTATIONS, WHETHER EXPRESS
OR IMPLIED, ARISING BY LAW, CUSTOM, PRIOR ORAL OR WRITTEN STATEMENT BY THE PARTIES, OR OTHERWISE (INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT) ARE HEREBY OVERRIDDEN, EXCLUDED AND
DISCLAIMED. 
 ARTICLE 10 
 INDEMNIFICATION 
 10.1 Indemnification by Cornerstone. Cornerstone
hereby agrees to defend Chiesi and its Affiliates and their respective directors, officers, employees, agents, successors and assigns from and against any and all Claims of a Third Party and to indemnify and hold Chiesi and its Affiliates and their
respective directors, officers, employees, agents, successors and assigns, harmless from and against any and all Losses to the extent arising from any such Claims 

  
 22 

 
of a Third Party for (i) death or personal injury to the extent arising from the manufacture, supply, importation, storage, handling, use, promotion, distribution, marketing, sale, use or
consumption of the Compound and/or the Product, (ii) Cornerstone’s breach of its representations, warranties or covenants under this Agreement, or Pharmacovigilance Agreement, or (iii) the negligence or willful misconduct or
wrongdoing of Cornerstone or any person for whose actions or omissions Cornerstone is legally liable, except, in each case, to the extent that such Losses arise as a result of an item for which Chiesi is obligated to indemnify Cornerstone pursuant
to Section 10.2. 
 10.2 Indemnification by Chiesi. Chiesi hereby agrees to defend Cornerstone and its Affiliates
and their respective directors, officers, employees, agents, successors and assigns from and against any and all Claims of a Third Party and to indemnify and hold Cornerstone and its Affiliates and their respective directors, officers, employees,
agents, successors and assigns, harmless from and against any and all Losses to the extent arising from any such Claims of a Third Party for (i) Chiesi’s breach of its representations, warranties or covenants under this Agreement or
Pharmacovigilance Agreement, or (ii) the negligence or willful misconduct or wrongdoing of Chiesi or any person for whose actions or omissions Chiesi is legally liable, except, in each case, to the extent that such Losses arise as a result of
an item for which Cornerstone is obligated to indemnify Chiesi pursuant to Section 10.1. 
 10.3 Indemnification
Procedures. No indemnity may be claimed by or given to the Party seeking to rely on such indemnity: 
 10.3.1 unless
the Party claiming indemnity shall have promptly notified the other Party of the relevant potential Loss upon becoming aware of such potential Loss except to the extent the failure to provide such notice does not materially prejudice the Party
providing such indemnity’s ability to defend or contest any suit or claim relating to such potential Loss; 
 10.3.2
where the Party seeking indemnification has made any admission or offer or any settlement without the prior written consent of the indemnifying Party, which consent shall not be unreasonably withheld or delayed; and 

10.3.3 unless the Party seeking indemnification has allowed the indemnifying Party to assume full control of all proceedings in
relation to any such potential Loss within thirty (30) days of having been given notice of such proceedings; provided, that (i) the Party seeking indemnification shall have the right to appoint independent counsel at its own cost to
participate therein and (ii) no compromise or settlement may be effected by the indemnifying Party without the prior written consent of the other Party. 
 10.4 Insurance. During the Term and for a period of thirty-six (36) months thereafter, the Parties shall obtain and/or maintain product liability insurance in such amounts as are reasonable
given (i) their responsibilities and liabilities under this Agreement and (ii) such amounts as may be reasonable and customary within the industry in respect of the Product and country the subject of this Agreement. On request, either
Party shall provide the other Party with a certificate of such insurance policy. 

  
 23 

 10.5 Limitation on Liability. NOTWITHSTANDING THE FOREGOING WARRANTIES AND
REPRESENTATIONS AND THE FURTHER OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT, EXCEPT FOR EACH PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO THIS ARTICLE 10, AND SUBJECT TO ANY EXPRESS PROVISION TO THE CONTRARY, NEITHER PARTY SHALL BE
LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, STATUTORY, TREBLE, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING ANY CLAIM FOR DAMAGES BASED UPON LOST PROFITS OR LOST BUSINESS OPPORTUNITY EXCEPT WHERE SUCH DAMAGES ARE THE RESULT OF
EITHER PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. 
 ARTICLE 11 

CONFIDENTIALITY 
 11.1 Confidential Information. Each Party acknowledges that the other Party may disclose certain information, data or know-how which the disclosing Party treats confidentially and identifies as
confidential or which the recipient knows or should have reason to believe is so treated by the disclosing Party (the “Confidential Information”). If either Party discloses such Confidential Information to the other, the receiving
Party will (a) use at least the same degree of care to maintain the secrecy of such Confidential Information as the receiving Party uses to maintain the secrecy of its own confidential information, but in no event less than a reasonable degree
of care and (b) use the Confidential Information only to accomplish the purposes of this Agreement. 
 11.2
Disclosure. The receiving Party will not disclose the Confidential Information of the disclosing Party to any person except those of the receiving Party’s employees or agents that require access thereto to accomplish the purposes of this
Agreement and have been made aware of the confidentiality obligations herein. If the receiving Party learns of an actual or potential unauthorized use or disclosure of the disclosing Party’s Confidential Information, the receiving Party will
promptly notify the disclosing Party and, at the disclosing Party’s request, provide the disclosing Party with reasonable assistance to recover its Confidential Information and to prevent subsequent unauthorized uses or disclosures of such
Confidential Information. Each Party acknowledges that (a) the unauthorized use or disclosure of any Confidential Information of the disclosing Party will cause irreparable damage for which it will not have an adequate remedy at law and
(b) the disclosing Party will be entitled to injunctive and other equitable relief in such cases. 
 11.3
Limitations. Neither Party will have any confidentiality obligation with respect to the Confidential Information of the disclosing Party that (a) the receiving Party independently knew or develops without using such Confidential Information
of the disclosing Party, (b) the receiving Party lawfully obtains from another person under no obligation of confidentiality or (c) is or becomes publicly available other than as a result of an act or omission of the receiving Party or any
of its employees or agents. 
 11.4 Terms of Agreement. Except as set forth below, no announcement or other disclosure,
public or otherwise, concerning the financial or other terms of this Agreement shall be made, either directly or indirectly, by either Party to this Agreement, except as may be legally 

  
 24 

 
required, without first obtaining the written approval of the other Party as to the nature and text of such announcement or disclosure, such approval and agreement not to be unreasonably
withheld. Notwithstanding the above, the Parties shall be free to publicly disclose information contained in such press release that has been previously approved for disclosure by the other Party, without further approvals from the other Party
hereunder, to the extent there have been no material additions or changes thereto. 
 11.5 Publication of Data. Any
publication of clinical and scientific data relevant to the Product, generated under the terms of this Agreement, will be jointly planned and agreed upon in advance. 
 11.6 Confidentiality Term. All confidentiality provisions set out herein shall remain in full force and effect during the Term and for a period of ten (10) years from the date of termination
hereof. 
 ARTICLE 12 
 TERM AND TERMINATION 
 12.1 Term. This Agreement
shall become effective on the Effective Date and shall remain in force until the last date on which the sale of the Product in the Territory would infringe a Valid Claim of an Orange Book Patent in the Territory but for the grant of the rights under
this Agreement (“Initial Term”). Thereafter, this Agreement shall automatically renew for an additional period of five (5) years (“Extended Term”), which Extended Term may be earlier terminated by either Party
with effect on December 31st of any year, by giving
at least twelve (12) months prior written notice. 
 12.2 Termination upon Marketing Authorization Denial or upon
Different Label Grant. In the event that the Marketing Authorization is not obtained by April 1, 2013, or in the event the Marketing Authorization is granted with a label that is materially different from that submitted with the NDA,
Cornerstone will have the right to terminate the Agreement upon thirty (30) Business Days’ prior written notice. 

12.3 Termination upon Adverse Agency Action. Notwithstanding anything contained in this Agreement, Cornerstone may terminate this
Agreement upon thirty (30) Business Days prior written notice in the event that any Agency takes any action, or raises any objection, that permanently prevents Cornerstone from importing, marketing or selling the Product in the Territory.

 12.4 Termination upon Regulatory Authority Action. In the event that a Regulatory Authority requires Cornerstone to
cease selling or distributing the Product in the Territory, Cornerstone will have the right to terminate the Agreement upon thirty (30) Business Days’ prior written notice. 

12.5 Termination upon Default or Breach. In the event that either Party materially breaches this Agreement, the breaching party
shall have the opportunity to cure such breach within (i) thirty (30) Business Days or (ii) a reasonably longer period if such breach is not capable of cure within thirty (30) Business Days, in each case after receipt of written
notice of such breach. If the breach is not cured by the breaching party within the applicable cure period, 

  
 25 

 
the non-breaching party shall be entitled to bring action against the breaching party to recover damages (other than indirect, inconsequential or punitive damages) arising from such breach. The
non-breaching party shall have the right to terminate this Agreement upon thirty (30) Business Days written notice (following the expiration of all cure periods) if it can prove that the consequences of the breaching party’s breach or
default have a material adverse effect on the economic value of this Agreement to such Party and that, absent termination, such material adverse effect will be permanent in nature. 

12.6 Effects of Expiration or Termination. Upon expiry or termination of this Agreement, for any reason whatsoever:

 12.6.1 Cornerstone shall promptly cease selling the Product (except Product currently in stock, subject to Section
12.6.5) and using the Know-How and the Trademark; 
 12.6.2 Cornerstone shall promptly relinquish and return free of
charge to Chiesi all pharmacological, toxicological and clinical original data in its possession and all technical information, and Know-How or material relating to the Product; provided, however, that Chiesi shall reimburse Cornerstone for
reasonable out-of-pocket costs in connection with such return in the event of termination of this Agreement by Cornerstone pursuant to Sections 12.2, 12.3, 12.4 or 12.5; 
 12.6.3 Cornerstone shall promptly transfer free of charge to Chiesi, or to a company designated by Chiesi, any and all IND(s), Marketing Authorization Application(s) and Marketing Authorization
held by Cornerstone; provided, however, that Chiesi shall reimburse Cornerstone for reasonable out-of-pocket costs, including administrative transfer fees, in connection with such transfer in the event of termination of this Agreement by Cornerstone
pursuant to Sections 12.2, 12.3, 12.4 or 12.5. 
 12.6.4 the liabilities of the Parties hereunder in respect of matters
outstanding at the time of such termination shall not be in any way affected; 
 12.6.5 Chiesi shall have the option to
purchase all stocks of the Product, held by Cornerstone within thirty (30) days of termination, in good and marketable condition at supply price to Cornerstone. If the said option to purchase the above stock of the Product is not exercised by
Chiesi, Cornerstone shall be entitled to continue to sell the above stock of the Product in the Territory until all existing inventory is sold or for a period of six (6) months, whichever is shorter. 

12.6.6 Sections 8.6.3, 8.6.7 and 8.7 and Articles 10, 11 and 13 shall survive termination of this Agreement. 

12.7 Accrued Rights. Any termination of this Agreement shall be without prejudice to the rights and remedies of either Party with
respect to any of the provisions of this Agreement or arising out of breaches prior to such termination and shall not relieve either of the Parties of any obligations or liability accrued hereunder prior to such termination including indemnity
obligations and confidentiality obligations, nor rescind or give rise to any right to rescind anything done or payments made or other consideration given hereunder prior to the time of such termination and shall not affect in any manner any vested
rights of either Party arising out of this Agreement prior to such termination or expiration. 

  
 26 

 ARTICLE 13 

GENERAL PROVISIONS 
 13.1 No Restriction on Activities. Except as otherwise provided in this Agreement, nothing provided herein shall in any way limit the Parties from entering into any other business venture or
restrict Chiesi from entering into similar marketing or sales agreements with other persons or entities for the sale and distribution of other products or services, provided, however, that Chiesi shall not grant a license to any product to be used
essentially in the Competitive Field in the Territory to any Third Party without first offering an equivalent license to Cornerstone for the sale and distribution thereof at the terms set out below (“First Offer Right”). Chiesi shall grant
Cornerstone an exclusive First Offer Right for a period of sixty (60) days following receipt by Cornerstone of written notice by Chiesi that such product will be available for distribution (the “Negotiation Period”). If the
Parties do not reach an agreement with respect to the distribution of such product within the Negotiation Period and enter into a definitive agreement within ninety (90) days thereafter or if Cornerstone notifies Chiesi in writing during the
Negotiation Period that it does not wish to distribute such product, then Chiesi shall have no further obligation with respect to such product under this Section 13.1. 
 13.2 Legal Relationship. It is understood and agreed by the Parties that Cornerstone is an independent contractor and is not the agent of Chiesi for any purpose whatsoever, and Cornerstone has no
right or authority in any way to obligate, assume or create any liability on the part of Chiesi or to make any representations or warranties, whether express or implied, on behalf of Chiesi, except as permitted by this Agreement. 

13.3 Authority. Neither Chiesi nor Cornerstone shall have, or represent that it has, any authority to enter into or make contracts
in the name of, or on behalf of the other, to pledge the other’s credit, to extend credit to the other or to bind the other in any way. 
 13.4 Additions or Alterations to Chiesi’s Products. Cornerstone shall not make any additions, modifications or alterations to any Products without Chiesi’s prior written consent, which
Chiesi may withhold in its absolute discretion. 
 13.5 Assignment; Binding Effect. Neither this Agreement nor any rights
or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other, except that (i) Chiesi may assign this Agreement to any entity controlled by, under common control with or
controlling Chiesi and (ii) either party may assign this Agreement to any successor to such party by means of sale of all or substantially all of the assets of such party or sale of a majority of its voting stock. Subject to the foregoing, this
Agreement is binding upon, inures to the benefit of and is enforceable by the Parties to this Agreement and their respective successors and assigns. 
 13.6 No Third-Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of each Party hereto and their respective successors or permitted assigns, and it
is not the intention of the Parties to confer third-party beneficiary rights upon any other person. 

  
 27 

 13.7 Governing Law; Jurisdiction. Any and all rights, liabilities and any disputes
relating to this Agreement shall be construed under and governed by the laws of Italy. In the event of any controversy or claim arising out of or relating to or in connection with any provision of this Agreement or breach thereof, the Parties shall
try to settle those conflicts amicably between themselves. Should they fail to agree, the matter in dispute shall be finally and exclusively referred to the courts in England having jurisdiction. 

13.8 Entire Agreement. This Agreement constitutes the entire Agreement between the Parties hereto with respect to the subject
matter and supersedes all previous agreements, whether written or oral, with respect to such subject matter. No modification or alteration shall be binding unless in writing and signed by both Parties. 

13.9 Notices. All notices and other communications sent to the applicable address or facsimile number specified below shall be
deemed to have been delivered at the earlier of (i) the time of actual receipt by the addressee; (ii) if the notice is sent by facsimile transmission, the time indicated on the transmitting party’s receipt of confirmation of
transmission if that time is during the addressee’s regular business hours on a Business Day, and otherwise at 9:00 a.m. on the addressee’s next Business Day after such time; and (iii) if the notice is sent by a internationally
recognized, reputable express courier service, the time shown on the confirmation of delivery provided by that service if that time is during the recipient’s regular business hours on a Business Day, and otherwise at 9:00 a.m. on the
recipient’s next Business Day after such time. 
 Notices to Chiesi shall be addressed to: 

Chiesi Farmaceutici S.p.A. 
 Via Palermo 26/A 
 43122 Parma 

ITALY 
 Phone: +39.0521.2791 
 Fax: +39.0521.774468 

Attention: Chief Executive Officer 

Copy to: Head of Corporate Development and Legal and Corporate Affairs Director 

Notices to Cornerstone shall be addressed to: 
 Cornerstone Therapeutics Inc. 
 1255 Crescent Green Drive

 Suite 250 
 Cary, North Carolina 27518 
 USA 

Phone: 919-678-6611 
 Fax: 919-678-6599 
 Attention: President 

Copy to: General Counsel 
 Either Party may change its address by giving notice to the other Party. 

  
 28 

 13.10 Counterparts. This Agreement (and any amendments hereto) may be executed in
several counterparts (including by facsimile) and all when so executed shall constitute one agreement, binding on all of the Parties hereto, even though all of the Parties are not signatories to the original or the same counterpart. 

13.11 Severability. If any provision of this Agreement, or the application of such provision to any person or circumstance
shall be held invalid or in violation of a mandatory provision of Applicable Laws by a court or governmental agency of competent jurisdiction over this Agreement, it shall be ineffective and deemed to have been deleted from this Agreement only to
the extent of such invalidity or violations and the remainder of this Agreement, or the application of such provision to persons or circumstances other than those as to which it is held invalid, shall not be affected thereby. 

13.12 Waiver. Subject to Applicable Laws and except as otherwise provided in this Agreement, any Party to this Agreement may
extend the time for performance of any obligation under this Agreement of any other Party or waive compliance with any term or condition of this Agreement by any other Party. No such extension or waiver shall be effective unless set forth in a
written instrument duly executed by the Party granting such extension or waiver. No delay in asserting or exercising a right under this Agreement shall be deemed a waiver of that right. 

13.13 Further Assurances. At the request of either of the Parties, the other Party shall (and shall use reasonable efforts to
procure that any other necessary Third Parties shall) execute and do all such documents, acts and things as may reasonably be required subsequent to the signing of this Agreement for assuring to or vesting in the requesting Party the full benefit of
the terms hereof. 
 13.14 Headings. The headings herein are for the convenience of the Parties only and shall not be
used in the interpretation of the provisions hereof. 
 13.15 Publicity. Except as required by Applicable Law or stock
exchange, including Securities and Exchange Commission, rules, the Parties agree to keep this Agreement confidential until and except as they mutually agree on publicity. Subject to Applicable Law, all publicity regarding this Agreement shall be
jointly planned and coordinated by and between the Parties. 
 13.16 Force Majeure. Failure of either Party to perform
its obligations under this Agreement (excepting the obligation to make payments) shall not subject such Party to any liability to the other if such failure is caused or occasioned by any Force Majeure. The Party suffering an event of Force Majeure
shall immediately notify the other Party and the Parties shall cooperate in good faith in order to minimize the damages for the Parties; provided, however, that 

  
 29 

 
the Party whose performance has not been hindered by the Force Majeure shall have the right to terminate this Agreement, upon 30 (thirty) calendar days’ prior notice to the other, if an
event of Force Majeure continues for more than 6 (six) consecutive months. Termination pursuant to the application of this Section 13.16 shall not constitute a breach of this Agreement on the part of either Party. 

13.17 Language. All written communication between the Parties or their Affiliates relating to this Agreement and its
implementation shall be in English language. 
 [Signature Page Follows] 

  
 30 

 IN WITNESS THEREOF, the Parties hereto have caused this Agreement to be duly executed
in duplicate by their authorized officers as of the Effective Date. 
  

									
	CHIESI FARMACEUTICI S.p.A.	 		 	CORNERSTONE THERAPEUTICS INC.
					
	By:	 	/s/ Ugo Di Francesco	 		 	By:	 	/s/ Craig Collard
	Name:	 	Dr. Ugo Di Francesco	 		 	Name:	 	Craig A. Collard
	Title:	 	CEO	 		 	Title:	 	President and CEO
			
	CHIESI FARMACEUTICI S.p.A.	 		 	
					
	By:	 	/s/ Alberto Chiesi	 		 		 	
	Name:	 	Dr. Alberto Chiesi	 		 		 	
	Title:	 	Chairman	 		 		 	

 Appendix A 

to the License and Distribution Agreement made as of this 6th day of November, 2012 between Chiesi FARMACEUTICI S.p.A. and Cornerstone THERAPEUTICS Inc. 

Trademark 
 [To be indicated in
due course] 
 Patents listed in the Orange Book (upon NDA approval) 
 US 6,987,094 granted on 17.01.2006 
 US 7,696,178 granted on 13.04.2010 

US 7,939,502 granted on 10.05.2011 
 Other
Patents 
 US 8,168,598 granted on 01.05.2012 
 Apl. nr. 13/429,624 filed on 26.03.2012 
  

					
	Chiesi FARMACEUTICI S.p.A.	 		 	Cornerstone THERAPEUTICS Inc.
			
	/s/ Ugo Di Francesco	 		 	/s/ Craig Collard
	(Signature)	 		 	(Signature)
			
	Chiesi FARMACEUTICI S.p.A.	 		 	
			
	/s/ Alberto Chiesi	 		 	
	(Signature)	 		 	

 Exhibit A 
 Supply Agreement 

 Exhibit B 
 Manufacturing Agreement 

 Schedule 
  

			
		
	1.33	  	[Current Draft Product Specs, to be updated upon FDA approval]Deposit Agreement

 Exhibit 4.2 

 
  

 
 DEPOSIT AGREEMENT 

between 

EverBank Financial Corp, 
 as Issuer 
 and 

Wells Fargo Bank, N.A. 
 as Depositary, 
 on behalf of 

 
 THE HOLDERS FROM TIME TO TIME OF 

THE DEPOSITARY RECEIPTS DESCRIBED HEREIN 
 Dated as of November 13, 2012 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	ARTICLE I	  
	
	DEFINED TERMS	  
			
	Section 1.1.	 	Definitions.	  	 	1	  
	
	ARTICLE II	  
	
	FORM OF RECEIPTS, DEPOSIT OF STOCK, EXECUTION
AND DELIVERY, TRANSFER, SURRENDER AND REDEMPTION OF RECEIPTS	
  
			
	Section 2.1.	 	Form and Transfer of Receipts.	  	 	3	  
			
	Section 2.2.	 	Deposit of Stock; Execution and Delivery of Receipts in Respect Thereof.	  	 	4	  
			
	Section 2.3.	 	Registration of Transfer of Receipts.	  	 	5	  
			
	Section 2.4.	 	Split-ups and Combinations of Receipts; Surrender of Receipts and Withdrawal of Stock.	  	 	6	  
			
	Section 2.5.	 	Limitations on Execution and Delivery, Transfer, Surrender and Exchange of Receipts.	  	 	7	  
			
	Section 2.6.	 	Lost Receipts, etc.	  	 	7	  
			
	Section 2.7.	 	Cancellation and Destruction of Surrendered Receipts.	  	 	7	  
			
	Section 2.8.	 	Redemption of Stock.	  	 	8	  
			
	Section 2.9.	 	Receipts Issuable in Global Registered Form.	  	 	9	  
	
	ARTICLE III	  
	
	CERTAIN OBLIGATIONS OF HOLDERS OF RECEIPTS AND
THE COMPANY	  
			
	Section 3.1.	 	Filing Proofs, Certificates and Other Information.	  	 	10	  
			
	Section 3.2.	 	Payment of Taxes or Other Governmental Charges.	  	 	11	  
			
	Section 3.3.	 	Warranty as to Stock.	  	 	11	  
			
	Section 3.4.	 	Warranty as to Receipts.	  	 	11	  

  
 -i-

							
	ARTICLE IV	  
	
	THE DEPOSITED SECURITIES; NOTICES	  
			
	Section 4.1.	 	Cash Distributions.	  	 	11	  
			
	Section 4.2.	 	Distributions Other than Cash, Rights, Preferences or Privileges.	  	 	12	  
			
	Section 4.3.	 	Subscription Rights, Preferences or Privileges.	  	 	12	  
			
	Section 4.4.	 	Notice of Dividends, etc.; Fixing Record Date for Holders of Receipts.	  	 	13	  
			
	Section 4.5.	 	Voting Rights.	  	 	14	  
			
	Section 4.6.	 	Changes Affecting Deposited Securities and Reclassifications, Recapitalizations, etc.	  	 	14	  
			
	Section 4.7.	 	Delivery of Reports.	  	 	15	  
			
	Section 4.8.	 	Lists of Receipt Holders.	  	 	15	  
	
	ARTICLE V	  
	
	THE DEPOSITARY, THE DEPOSITARY’S AGENTS, THE
REGISTRAR AND THE COMPANY	  

			
	Section 5.1.	 	Maintenance of Offices, Agencies and Transfer Books by the Depositary; Registrar.	  	 	15	  
			
	Section 5.2.	 	Prevention of or Delay in Performance by the Depositary, the Depositary’s Agents, the Registrar or the Company.	  	 	16	  
			
	Section 5.3.	 	Obligations of the Depositary, the Depositary’s Agents, the Registrar and the Company.	  	 	17	  
			
	Section 5.4.	 	Resignation and Removal of the Depositary; Appointment of Successor Depositary.	  	 	18	  
			
	Section 5.5.	 	Corporate Notices and Reports.	  	 	19	  
			
	Section 5.6.	 	Indemnification by the Company.	  	 	19	  
			
	Section 5.7.	 	Fees, Charges and Expenses.	  	 	20	  
	
	ARTICLE VI	  
	
	AMENDMENT AND TERMINATION	  
			
	Section 6.1.	 	Amendment.	  	 	20	  
			
	Section 6.2.	 	Termination.	  	 	21	  

  
 -ii-

							
	ARTICLE VII	  
	
	MISCELLANEOUS	  
			
	Section 7.1.	 	Counterparts.	  	 	22	  
			
	Section 7.2.	 	Exclusive Benefit of Parties.	  	 	22	  
			
	Section 7.3.	 	Invalidity of Provisions.	  	 	22	  
			
	Section 7.4.	 	Notices.	  	 	22	  
			
	Section 7.5.	 	Depositary’s Agents.	  	 	23	  
			
	Section 7.6.	 	Appointment of Registrar and Transfer Agent in Respect of the Receipts.	  	 	23	  
			
	Section 7.7.	 	Holders of Receipts Are Parties.	  	 	24	  
			
	Section 7.8.	 	Governing Law.	  	 	24	  
			
	Section 7.9.	 	Inspection of Deposit Agreement.	  	 	24	  
			
	Section 7.10.	 	Headings.	  	 	24	  
			
	Exhibit A	 	Form of Receipt	  	 	A-1	  
			
	Exhibit B	 	Certificate of Designations	  	 	B-1	  

  
 -iii-

 DEPOSIT AGREEMENT dated as of November 13, 2012, between EverBank Financial Corp, a
Delaware corporation and Wells Fargo Bank, N.A., a national banking association formed under the laws of the United States, as Depositary on behalf of the holders from time to time of the Receipts described herein. 

WHEREAS, it is desired to provide, as hereinafter set forth in this Deposit Agreement, for the deposit of shares of 6.75% Series A
Non-Cumulative Perpetual Preferred Stock of the Corporation with the Depositary for the purposes set forth in this Deposit Agreement and for the issuance hereunder of Depositary Shares representing a fractional interest in the Stock deposited and
for the execution and delivery of Receipts evidencing Depositary Shares; 
 WHEREAS, the Receipts are to be substantially in the
form of Exhibit A annexed hereto, with appropriate insertions, modifications and omissions, as hereinafter provided in this Deposit Agreement; and 
 WHEREAS, the terms and conditions of the 6.75% Series A Non-Cumulative Perpetual Preferred Stock of the Corporation are substantially set forth in the Certificate of Designations attached hereto as
Exhibit B; 
 NOW, THEREFORE, in consideration of the premises, the parties hereto agree as follows: 

ARTICLE I 

DEFINED TERMS 
  

	 	Section 1.1.	Definitions. 

 The
following definitions shall for all purposes, unless otherwise indicated, apply to the respective terms (in the singular and plural forms of such terms) used in this Deposit Agreement and the Receipts: 

“Certificate of Designations” shall mean the Certificate of Designations filed with the Secretary of State of the State
of Delaware establishing the Stock as a series of preferred stock of the Corporation, and setting forth the rights, preferences and privileges of the Stock, and attached hereto as Exhibit B, and as such certificate may be amended or restated from
time to time. 
 “Corporation” shall mean EverBank Financial Corp, a Delaware corporation, and its successors.

 “Deposit Agreement” shall mean this Deposit Agreement, as the same may be amended, modified or supplemented
from time to time in accordance with the terms hereof. 
 “Depositary” shall mean Wells Fargo Bank, N.A., a
national banking association formed under the laws of the United States and any successor as Depositary hereunder. 

  
 1 

 “Depositary Shares” shall mean the security representing a 1/1000th
fractional interest in a share of the Stock, and the same proportionate interest in any and all other property received by the Depositary in respect of such share of Stock and held under this Deposit Agreement, all as evidenced by the Receipts
issued hereunder. Subject to the terms of this Deposit Agreement, each owner of a Depositary Share is entitled, proportionately, to all the rights, preferences and privileges of the Stock represented by such Depositary Share (including the dividend,
voting, redemption and liquidation rights contained in the Certificate of Designations). 
 “Depositary’s
Agent” shall mean an agent appointed by the Depositary pursuant to Section 7.5. 
 “Depositary’s
Office” shall mean the principal office of the Depositary, at which at any particular time its depositary receipt business in respect of matters governed by this Deposit Agreement shall be administered. 

“Exchange Event” shall mean with respect to any Global Registered Receipt: 

(1) (A) the Global Receipt Depository which is the holder of such Global Registered Receipt or Receipts notifies the Corporation
that it is no longer willing or able to properly discharge its responsibilities under any Letter of Representations or that it is no longer eligible or in good standing under the Securities Exchange Act of 1934, as amended, and (B) the
Corporation has not appointed a qualified successor Global Receipt Depository within ninety (90) calendar days after the Corporation received such notice, or 
 (2) the Corporation in its sole discretion notifies the Depositary in writing that the Receipts or portion thereof issued or issuable in the form of one or more Global Registered Receipts shall no longer
be represented by such Global Registered Receipt or Receipts. 
 “Global Receipt Depository” shall mean, with
respect to any Receipt issued hereunder, The Depository Trust Company (“DTC”) or such other entity designated as Global Receipt Depository by the Corporation in or pursuant to this Deposit Agreement, which Person must be, to the extent
required by any applicable law or regulation, a clearing agency registered under the Securities Exchange Act of 1934, as amended. 
 “Global Registered Receipts” shall mean a global registered Receipt registered in the name of a nominee of DTC. 
 “Letter of Representations” shall mean any applicable agreement among the Corporation, the Depositary and a Global Receipt Depository with respect to such Global Receipt Depository’s
rights and obligations with respect to any Global Registered Receipts, as the same may be amended, supplemented, restated or otherwise modified from time to time and any successor agreement thereto. 

“Receipt” shall mean a receipt issued hereunder to evidence one or more Depositary Shares held of record by the record
holder of such Depositary Shares, whether in definitive or temporary form, substantially in the form set forth as Exhibit A. 

  
 2 

 “record holder” or “holder” as applied to a Receipt shall
mean the person in whose name a Receipt is registered on the books of the Depositary maintained by the Depositary for such purpose. 
 “Redemption Date” shall have the meaning set forth in Section 2.8. 
 “Redemption Price” shall have the meaning set forth in the Certificate of Designations. 
 “Registrar” shall mean the Depositary or such other successor bank or trust company which shall be appointed by the Corporation to register ownership and transfers of Receipts as herein
provided and if a successor Registrar shall be so appointed, references herein to “the books” of or maintained by the Depositary shall be deemed, as applicable, to refer as well to the register maintained by such Registrar for such
purpose. 
 “Securities Act” shall mean the Securities Act of 1933, as amended. 

“Stock” shall mean shares of the Corporation’s 6.75% Series A Non-Cumulative Perpetual Preferred Stock, $0.01 par
value, $25,000 liquidation preference per share, designated and described in the Certificate of Designations. 
 ARTICLE II

 FORM OF RECEIPTS, DEPOSIT OF STOCK,

 EXECUTION AND DELIVERY, TRANSFER, 

SURRENDER AND REDEMPTION OF RECEIPTS 

 

	 	Section 2.1.	Form and Transfer of Receipts. 

 Definitive Receipts shall be substantially in the form set forth in Exhibit A annexed to this Deposit Agreement, in each case with appropriate insertions, modifications and omissions, as hereinafter
provided and shall be engraved or otherwise prepared so as to comply with applicable rules of the New York Stock Exchange Inc. Pending the preparation of definitive Receipts, the Depositary, upon the written order of the Corporation, delivered in
compliance with Section 2.2, shall execute and deliver temporary Receipts which may be printed, lithographed, typewritten, mimeographed or otherwise substantially of the tenor of the definitive Receipts in lieu of which they are issued and with
such appropriate insertions, omissions, substitutions and other variations as the persons executing such Receipts may determine, as evidenced by their execution of such Receipts. If temporary Receipts are issued, the Corporation and the Depositary
will cause definitive Receipts to be prepared without unreasonable delay. After the preparation of definitive Receipts, the temporary Receipts shall be exchangeable for definitive Receipts upon surrender of the temporary Receipts at an office
described in the penultimate paragraph of Section 2.2, without charge to the Holder. Upon surrender for cancellation of any one or more temporary Receipts, the Depositary shall execute and deliver in exchange therefor definitive Receipts
representing the same number of 

  
 3 

 
Depositary Shares as represented by the surrendered temporary Receipt or Receipts. Such exchange shall be made at the Corporation’s expense and without any charge therefor. Until so
exchanged, the temporary Receipts shall in all respects be entitled to the same benefits under this Agreement as definitive Receipts. 
 Receipts shall be executed by the Depositary by the manual signature of a duly authorized officer of the Depositary; provided, that such signature may be a facsimile if a Registrar for the Receipts (other
than the Depositary) shall have been appointed and such Receipts are countersigned by a duly authorized officer of the Registrar. No Receipt shall be entitled to any benefits under this Deposit Agreement or be valid or obligatory for any purpose
unless it shall have been executed manually by a duly authorized officer of the Depositary or, if a Registrar for the Receipts (other than the Depositary) shall have been appointed, by manual or facsimile signature of a duly authorized officer of
the Depositary and countersigned by a duly authorized officer of such Registrar. The Depositary shall record on its books each Receipt so signed and delivered as hereinafter provided. 

Receipts shall be in denominations of any number of whole Depositary Shares. All receipts shall be dated the date of their issuance.

 Receipts may be endorsed with or have incorporated in the text thereof such legends or recitals or changes not inconsistent
with the provisions of this Deposit Agreement all as may be required by the Depositary and approved by the Corporation or required to comply with any applicable law or any regulation thereunder or with the rules and regulations of any securities
exchange upon which the Stock, the Depositary Shares or the Receipts may be listed or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to which any particular Receipts are subject. 

Title to Depositary Shares evidenced by a Receipt which is properly endorsed or accompanied by a properly executed instrument of
transfer, shall be transferable by delivery with the same effect as in the case of a negotiable instrument; provided, however, that until transfer of any particular Receipt shall be registered on the books of the Depositary as provided in
Section 2.3, the Depositary may, notwithstanding any notice to the contrary, treat the record holder thereof at such time as the absolute owner thereof for the purpose of determining the person entitled to distributions of dividends or other
distributions or to any notice provided for in this Deposit Agreement and for all other purposes. 
  

	 	Section 2.2.	Deposit of Stock; Execution and Delivery of Receipts in Respect Thereof. 

 Subject to the terms and conditions of this Deposit Agreement, the Corporation may from time to time deposit shares of the Stock under this Deposit Agreement by delivery to the Depositary of (i) a
certificate or certificates for the Stock to be deposited, properly endorsed or accompanied, if required by the Depositary, by a duly executed instrument of transfer or endorsement or (ii) an instruction letter from the Corporation authorizing
the 

  
 4 

 
Depositary to register such shares of the Stock in book-entry form, each in form satisfactory to the Depositary, together with all such certifications as may be required by the Depositary in
accordance with the provisions of this Deposit Agreement and all other information required to be set forth, and together with a written order of the Corporation directing the Depositary to execute and deliver to, or upon the written order of, the
person or persons stated in such order a Receipt or Receipts evidencing in the aggregate the number of Depositary Shares representing such deposited Stock. 
 Deposited Stock shall be held by the Depositary at the Depositary’s Office or at such other place or places as the Depositary shall determine. The Depositary shall not lend any Stock deposited
hereunder. 
 Upon receipt by the Depositary of (i) a certificate or certificates for Stock deposited in accordance with
the provisions of this Section or (ii) an instruction letter from the Corporation in accordance with the provisions of this Section, together with the other documents required as above specified, and upon recordation of the Stock on the books
of the Corporation (or its duly appointed transfer agent) in the name of the Depositary or its nominee, the Depositary, subject to the terms and conditions of this Deposit Agreement, shall execute and deliver to or upon the order of the person or
persons named in the written order delivered to the Depositary referred to in the first paragraph of this Section, a Receipt or Receipts evidencing in the aggregate the number of Depositary Shares representing the Stock so deposited and registered
in such name or names as may be requested by such person or persons. The Depositary shall execute and deliver such Receipt or Receipts at the Depositary’s Office or such other offices, if any, as the Depositary may designate. Delivery at other
offices shall be at the risk and expense of the person requesting such delivery. 
  

	 	Section 2.3.	Registration of Transfer of Receipts. 

 Subject to the terms and conditions of this Deposit Agreement, the Depositary shall register on its books from time to time transfers of Receipts upon any surrender thereof by the holder in person or by
duly authorized attorney, properly endorsed or accompanied by a properly executed instrument of transfer. Thereupon, the Depositary shall execute a new Receipt or Receipts evidencing the same aggregate number of Depositary Shares as those evidenced
by the Receipt or Receipts surrendered and deliver such new Receipt or Receipts to or upon the order of the person entitled thereto. 
 The Depositary shall not be required (a) to issue, transfer or exchange any Receipts for a period beginning at the opening of business fifteen days next preceding any selection of Depositary Shares
and Stock to be redeemed and ending at the close of business on the day of the mailing of notice of redemption, or (b) to transfer or exchange for another Receipt any Receipt called or being called for redemption in whole or in part except as
provided in Section 2.8. 

  
 5 

	 	Section 2.4.	Split-ups and Combinations of Receipts; Surrender of Receipts and Withdrawal of Stock. 

Upon surrender of a Receipt or Receipts at the Depositary’s Office or at such other offices as it may designate for the purpose of
effecting a split-up or combination of such Receipt or Receipts, and subject to the terms and conditions of this Deposit Agreement, the Depositary shall execute a new Receipt or Receipts in the authorized denomination or denominations requested,
evidencing the aggregate number of Depositary Shares evidenced by the Receipt or Receipts surrendered, and shall deliver such new Receipt or Receipts to or upon the order of the holder of the Receipt or Receipts so surrendered. 

Any holder of a Receipt or Receipts may withdraw the number of whole shares of Stock and all money and other property, if any,
represented thereby by surrendering such Receipt or Receipts, at the Depositary’s Office or at such other offices as the Depositary may designate for such withdrawals. Thereafter, without unreasonable delay, the Depositary shall deliver to such
holder, or to the person or persons designated by such holder as hereinafter provided, the number of whole shares of Stock and all money and other property, if any, represented by the Receipt or Receipts so surrendered for withdrawal, but holders of
such whole shares of Stock will not thereafter be entitled to deposit such Stock hereunder or to receive a Receipt evidencing Depositary Shares therefor. If a Receipt delivered by the holder to the Depositary in connection with such withdrawal shall
evidence a number of Depositary Shares in excess of the number of Depositary Shares representing the number of whole shares of Stock to be so withdrawn, the Depositary shall at the same time, in addition to such number of whole shares of Stock and
such money and other property, if any, to be so withdrawn, deliver to such holder, or subject to Section 2.3 upon such holder’s order, a new Receipt evidencing such excess number of Depositary Shares. 

Except as provided in Section 6.2, in no event will fractional shares of Stock (or any cash payment in lieu thereof) be delivered by
the Depositary. Delivery of the Stock and money and other property, if any, being withdrawn may be made by the delivery of such certificates, documents of title and other instruments as the Depositary may deem appropriate. 

If the Stock and the money and other property, if any, being withdrawn are to be delivered to a person or persons other than the record
holder of the Receipt or Receipts being surrendered for withdrawal of Stock, such holder shall execute and deliver to the Depositary a written order so directing the Depositary and the Depositary may require that the Receipt or Receipts surrendered
by such holder for withdrawal of such shares of Stock be properly endorsed in blank or accompanied by a properly executed instrument of transfer in blank. 
 Delivery of the Stock and the money and other property, if any, represented by Receipts surrendered for withdrawal shall be made by the Depositary at the Depositary’s Office, except that, at the
request, risk and expense of the holder surrendering such Receipt or Receipts and for the account of the holder thereof, such delivery may be made at such other place as may be designated by such holder. 

  
 6 

	 	Section 2.5.	Limitations on Execution and Delivery, Transfer, Surrender and Exchange of Receipts. 

As a condition precedent to the execution and delivery, registration of transfer, split-up, combination, surrender or exchange of any
Receipt, the Depositary, any of the Depositary’s Agents or the Corporation may require payment to it of a sum sufficient for the payment (or, in the event that the Depositary or the Corporation shall have made such payment, the reimbursement to
it) of any charges or expenses payable by the holder of a Receipt pursuant to Section 5.7, may require the production of evidence satisfactory to it as to the identity and genuineness of any signature, and any other reasonable evidence of
authority that may be required by the Depositary and may also require compliance with such regulations, if any, as the Depositary or the Corporation may establish consistent with the provisions of this Deposit Agreement and/or applicable law.

 The deposit of Stock may be refused, the delivery of Receipts against Stock may be suspended, the registration of transfer of
Receipts may be refused and the registration of transfer, surrender or exchange of outstanding Receipts may be suspended (i) during any period when the register of stockholders of the Corporation is closed or (ii) at any time or from time
to time because of any requirement of law or of any government or governmental body or commission or under any provision of this Deposit Agreement. 
  

	 	Section 2.6.	Lost Receipts, etc. 

 In
case any Receipt shall be mutilated, destroyed, lost or stolen, the Depositary in its discretion may execute and deliver a Receipt of like form and tenor in exchange and substitution for such mutilated Receipt, or in lieu of and in substitution for
such destroyed, lost or stolen Receipt, upon (i) the filing by the holder thereof with the Depositary of evidence satisfactory to the Depositary of such destruction or loss or theft of such Receipt, of the authenticity thereof and of such
holder’s ownership thereof and (ii) the holder thereof furnishing of the Depositary with reasonable indemnification satisfactory to the Depositary. 
  

	 	Section 2.7.	Cancellation and Destruction of Surrendered Receipts. 

 All Receipts surrendered to the Depositary or any Depositary’s Agent shall be cancelled by the Depositary. Except as prohibited by applicable law or regulation, the Depositary is authorized and
directed to destroy all Receipts so cancelled. 

  
 7 

	 	Section 2.8.	Redemption of Stock. 

Whenever the Corporation shall be permitted and shall elect to redeem shares of Stock in accordance with the provisions of the Certificate
of Designations (including on account of a Regulatory Capital Treatment Event, as described therein), it shall (unless otherwise agreed to in writing with the Depositary) give or cause to be given to the Depositary, not less than 30 days and
not more than 60 days prior to the Redemption Date (as defined below), notice of the date of such proposed redemption of Stock and of the number of such shares held by the Depositary to be so redeemed and the applicable redemption price, which
notice shall be accompanied by a certificate from the Corporation stating that such redemption of Stock is in accordance with the provisions of the Certificate of Designations. On the date of such redemption, provided that the Corporation shall then
have paid or caused to be paid in full to the Depositary the Redemption Price per share of Stock to be redeemed, in accordance with and as required by the provisions of the Certificate of Designations, the Depositary shall redeem the number of
Depositary Shares representing such Stock. The Depositary shall mail notice of the Corporation’s redemption of Stock and the proposed simultaneous redemption of the number of Depositary Shares representing the Stock to be redeemed shall be
(1) mailed by first-class mail, postage prepaid, at the respective last addresses as they appear on the records of the Depositary, or (2) transmitted by such other method approved by the Depositary, in its reasonable discretion, in either
case not less than 30 days and not more than 60 days prior to the date fixed for redemption of such Stock and Depositary Shares (the “Redemption Date”), to the record holders of the Receipts evidencing the Depositary Shares to be so
redeemed at the addresses of such holders as they appear on the records of the Depositary; but neither failure to mail or transmit any such notice of redemption of Depositary Shares to one or more such holders nor any defect in any notice of
redemption of Depositary Shares to one or more such holders shall affect the sufficiency of the proceedings for redemption as to the other holders. Each such notice shall be prepared by the Corporation and shall state: (i) the Redemption Date;
(ii) the number of Depositary Shares to be redeemed and, if less than all the Depositary Shares held by any such holder are to be redeemed, the number of such Depositary Shares held by such holder to be so redeemed; (iii) the redemption
price; (iv) the place or places where Receipts evidencing Depositary Shares are to be surrendered for payment of the redemption price and (v) that dividends on such shares of Stock represented by the Depositary Shares to be redeemed will
cease to accrue on such Redemption Date. In case less than all the outstanding Depositary Shares are to be redeemed, the Depositary Shares to be so redeemed shall be selected either pro rata , by lot or in such other manner as the Corporation
may determine to be equitable. 
 Notice having been mailed or transmitted by the Depositary as aforesaid, from and after the
Redemption Date (unless the Corporation shall have failed to provide the funds necessary to redeem the Stock evidenced by the Depositary Shares called for redemption) (i) all shares of Stock called for redemption shall cease to be outstanding
and any rights with respect to such shares shall cease and terminate (except for the right to receive the redemption price without interest), (ii) the Depositary Shares being redeemed from such proceeds shall cease to be outstanding and all
rights of the holders of Receipts evidencing 

  
 8 

 
such Depositary Shares shall, to the extent of such Depositary Shares, cease and terminate (except the right to receive the redemption price without interest), and (iii) upon surrender in
accordance with such redemption notice of the Receipts evidencing any such Depositary Shares called for redemption (properly endorsed or assigned for transfer, if the Depositary or applicable law shall so require), such Depositary Shares shall be
redeemed by the Depositary at a redemption price per Depositary Share equal to one-thousandth of the Redemption Price per share of Stock so redeemed plus all money and other property, if any, represented by such Depositary Shares. 

If fewer than all of the Depositary Shares evidenced by a Receipt are called for redemption, the Depositary will deliver to the holder of
such Receipt upon its surrender to the Depositary, together with the redemption payment, a new Receipt evidencing the Depositary Shares evidenced by such prior Receipt and not called for redemption. 

 

	 	Section 2.9.	Receipts Issuable in Global Registered Form. 

 If the Corporation shall determine in a writing delivered to the Depositary that the Receipts are to be issued in whole or in part in the form of one or more Global Registered Receipts, then the
Depositary shall, in accordance with the other provisions of this Deposit Agreement, execute and deliver one or more Global Registered Receipts evidencing such Receipts, which (i) shall represent, and shall be denominated in an amount equal to
the aggregate principal amount of, the Receipts to be represented by such Global Registered Receipt or Receipts, and (ii) shall be registered in the name of the Global Receipt Depository therefor or its nominee. 

Notwithstanding any other provision of this Deposit Agreement to the contrary, unless otherwise provided in the Global Registered
Receipt, a Global Registered Receipt may only be transferred in whole and only by the applicable Global Receipt Depository for such Global Registered Receipt to a nominee of such Global Receipt Depository, or by a nominee of such Global Receipt
Depository to such Global Receipt Depository or another nominee of such Global Receipt Depository, or by such Global Receipt Depository or any such nominee to a successor Global Receipt Depository for such Global Registered Receipt selected or
approved by the Corporation or to a nominee of such successor Global Receipt Depository. Except as provided below, owners solely of beneficial interests in a Global Registered Receipt shall not be entitled to receive physical delivery of the
Receipts represented by such Global Registered Receipt. Neither any such beneficial owner nor any direct or indirect participant of a Global Receipt Depository shall have any rights under this Deposit Agreement with respect to any Global Registered
Receipt held on their behalf by a Global Receipt Depository and such Global Receipt Depository may be treated by the Corporation, the Depositary and any director, officer, employee or agent of the Corporation or the Depositary as the holder of such
Global Registered Receipt for all purposes whatsoever. 
 Unless and until definitive Receipts are delivered to the owners of
the beneficial interests in a Global Registered Receipt, (1) the applicable Global Receipt Depository 

  
 9 

 
will make book-entry transfers among its participants and receive and transmit all payments and distributions in respect of the Global Registered Receipts to such participants, in each case, in
accordance with its applicable procedures and arrangements, and (2) whenever any notice, payment or other communication to the holders of Global Registered Receipts is required under this Deposit Agreement, the Corporation and the Depositary
shall give all such notices, payments and communications specified herein to be given to such holders to the applicable Global Receipt Depository. 
 If an Exchange Event has occurred with respect to any Global Registered Receipt, then, in any such event, the Depositary shall, upon receipt of a written order from the Corporation for the execution and
delivery of individual definitive registered Receipts in exchange for such Global Registered Receipt, execute and deliver, individual definitive registered Receipts, in authorized denominations and of like tenor and terms in an aggregate principal
amount equal to the principal amount of the Global Registered Receipt surrendered in exchange for such Global Registered Receipt. 
 Definitive registered Receipts issued in exchange for a Global Registered Receipt pursuant to this Section shall be registered in such names and in such authorized denominations as the Global Receipt
Depository for such Global Registered Receipt, pursuant to instructions from its participants, shall instruct the Depositary in writing. The Depositary shall deliver such Receipts to the persons in whose names such Receipts are so registered.

 Notwithstanding anything to the contrary in this Deposit Agreement, should the Corporation determine that the Receipts should
be issued as a Global Registered Receipt, the parties hereto shall comply with the terms of each Letter of Representations, if applicable. 
 ARTICLE III 
 CERTAIN OBLIGATIONS OF

 HOLDERS OF RECEIPTS AND THE COMPANY

  

	 	Section 3.1.	Filing Proofs, Certificates and Other Information. 

 Any holder of a Receipt may be required from time to time to file such proof of residence, or other matters or other information, to execute such certificates and to make such representations and
warranties as the Depositary or the Corporation may reasonably deem necessary or proper. The Depositary or the Corporation may withhold the delivery, or delay the registration of transfer or redemption, of any Receipt or the withdrawal of the Stock
represented by the Depositary Shares evidenced by any Receipt or the distribution of any dividend or other distribution or the sale of any rights or of the proceeds thereof until such proof or other information is filed or such certificates are
executed or such representations and warranties are made. 

  
 10 

	 	Section 3.2.	Payment of Taxes or Other Governmental Charges. 

 Holders of Receipts shall be obligated to make payments to the Depositary of certain charges and expenses, as provided in Section 5.7. Registration of transfer of any Receipt or any withdrawal of
Stock and all money or other property, if any, represented by the Depositary Shares evidenced by such Receipt may be refused until any such payment due is made, and any dividends or other distributions may be withheld or any part of or all the Stock
or other property represented by the Depositary Shares evidenced by such Receipt and not theretofore sold may be sold for the account of the holder thereof (after attempting by reasonable means to notify such holder prior to such sale), and such
dividends or other distributions or the proceeds of any such sale may be applied to any payment of such charges or expenses, the holder of such Receipt remaining liable for any deficiency. 

 

	 	Section 3.3.	Warranty as to Stock. 

The Corporation hereby represents and warrants that the Stock, when issued, will be duly authorized, validly issued, fully paid and
nonassessable. Such representation and warranty shall survive the deposit of the Stock and the issuance of Receipts. 
  

	 	Section 3.4.	Warranty as to Receipts. 

The Corporation hereby represents and warrants that the Receipts, when issued, will represent legal and valid interests in the Stock. Such
representation and warranty shall survive the deposit of the Stock and the issuance of Receipts. 
 ARTICLE IV 

THE DEPOSITED SECURITIES; NOTICES 

 

	 	Section 4.1.	Cash Distributions. 

Whenever the Depositary shall receive any cash dividend or other cash distribution on Stock, the Depositary shall, subject to Sections 3.1
and 3.2, distribute to record holders of Receipts on the record date fixed pursuant to Section 4.4 such amounts of such dividend or distribution as are, as nearly as practicable, in proportion to the respective numbers of Depositary Shares
evidenced by the Receipts held by such holders; provided, however, that in case the Corporation or the Depositary shall be required to withhold and shall withhold from any cash dividend or other cash distribution in respect of the Stock an amount on
account of taxes, the amount made available for distribution or distributed in respect of Depositary Shares shall be reduced accordingly. The Depositary shall distribute or make available for distribution, as the case may be, only such amount,
however, as can be distributed without attributing to any holder of Receipts a fraction of one cent, and any balance not so distributable shall be held by the Depositary (without liability for interest thereon) and shall be added to and be treated
as part of the next sum 

  
 11 

 
received by the Depositary for distribution to record holders of Receipts then outstanding. Each holder of a Receipt shall provide the Depositary with its certified tax identification number on a
properly completed Form W-8 or W-9, as may be applicable. Each holder of a Receipt acknowledges that, in the event of non-compliance with the preceding sentence, the Internal Revenue Code of 1986, as amended, may require withholding by the
Depositary of a portion of any of the distributions to be made hereunder. 
  

	 	Section 4.2.	Distributions Other than Cash, Rights, Preferences or Privileges. 

 Whenever the Depositary shall receive any distribution other than cash, rights, preferences or privileges upon Stock, the Depositary shall, at the direction of the Corporation, subject to Sections 3.1 and
3.2, distribute to record holders of Receipts on the record date fixed pursuant to Section 4.4 such amounts of the securities or property received by it as are, as nearly as practicable, in proportion to the respective numbers of Depositary
Shares evidenced by the Receipts held by such holders, in any manner that the Corporation may deem equitable and practicable for accomplishing such distribution. If in the opinion of the Depositary such distribution cannot be made proportionately
among such record holders in accordance with the direction of the Corporation, or if for any other reason (including any requirement that the Corporation or the Depositary withhold an amount on account of taxes) the Depositary deems, after
consultation with the Corporation, such distribution not to be feasible, the Depositary may, with the approval of the Corporation, adopt such method as it deems equitable and practicable for the purpose of effecting such distribution, including the
sale (at public or private sale) of the securities or property thus received, or any part thereof, in a commercially reasonable manner. The net proceeds of any such sale shall, subject to Sections 3.1 and 3.2, be distributed or made available for
distribution, as the case may be, by the Depositary to record holders of Receipts as provided by Section 4.1 in the case of a distribution received in cash. The Corporation shall not make any distribution of such securities or property to the
Depositary and the Depositary shall not make any distribution of such securities or property to the holders of Receipts unless the Corporation shall have provided an opinion of counsel stating that such securities or property have been registered
under the Securities Act or do not need to be registered in connection with such distributions. 
  

	 	Section 4.3.	Subscription Rights, Preferences or Privileges. 

 If the Corporation shall at any time offer or cause to be offered to the persons in whose names the Stock is recorded on the books of the Corporation any rights, preferences or privileges to subscribe for
or to purchase any securities or any rights, preferences or privileges of any other nature, such rights, preferences or privileges shall in each such instance be made available by the Depositary to the Record Holders of Receipts in such manner as
the Corporation shall direct and the Depositary shall agree, either by the issue to such Record Holders of warrants representing such rights, preferences or privileges or by such other method as may be approved by the Corporation in its discretion
with the acknowledgement of the Depositary; provided, however, that 

  
 12 

 
(i) if at the time of issue or offer of any such rights, preferences or privileges the Corporation determines that it is not lawful or (after consultation with the Depositary) not feasible
to make such rights, preferences or privileges available to Holders of Receipts by the issue of warrants or otherwise, or (ii) if and to the extent so instructed by Holders of Receipts who do not desire to exercise such rights, preferences or
privileges, then the Corporation, in its discretion (with acknowledgement of the Depositary, in any case where the Corporation has determined that it is not feasible to make such rights, preferences or privileges available), may, if applicable laws
or the terms of such rights, preferences or privileges permit such transfer, sell such rights, preferences or privileges at public or private sale, at such place or places and upon such terms as it may deem proper. The net proceeds of any such sale
shall, subject to Sections 3.1 and 3.2, be distributed by the Depositary to the Record Holders of Receipts entitled thereto as provided by Section 4.1 in the case of a distribution received in cash. 

The Corporation shall notify the Depositary whether registration under the Securities Act of the securities to which any rights,
preferences or privileges relate is required in order for holders of Receipts to be offered or sold the securities to which such rights, preferences or privileges relate, and the Corporation agrees with the Depositary that it will file promptly a
registration statement pursuant to such Act with respect to such rights, preferences or privileges and securities and use its reasonable best efforts and take all steps available to it to cause such registration statement to become effective
sufficiently in advance of the expiration of such rights, preferences or privileges to enable such holders to exercise such rights, preferences or privileges. In no event shall the Depositary make available to the holders of Receipts any right,
preference or privilege to subscribe for or to purchase any securities unless and until such registration statement shall have become effective, or the Corporation shall have provided to the Depositary an opinion of counsel to the effect that the
offering and sale of such securities to such holders are exempt from registration under the provisions of the Securities Act. 

The Corporation shall notify the Depositary whether any other action under the laws of any jurisdiction or any governmental or
administrative authorization, consent or permit is required in order for such rights, preferences or privileges to be made available to holders of Receipts, and the Corporation agrees with the Depositary that the Corporation will use its reasonable
best efforts to take such action or obtain such authorization, consent or permit sufficiently in advance of the expiration of such rights, preferences or privileges to enable such holders to exercise such rights, preferences or privileges.

  

	 	Section 4.4.	Notice of Dividends, etc.; Fixing Record Date for Holders of Receipts. 

 Whenever any cash dividend or other cash distribution shall become payable or any distribution other than cash shall be made, or if rights, preferences or privileges shall at any time be offered, with
respect to Stock, or whenever the Depositary shall receive notice of any meeting at which holders of Stock are entitled to vote or of which holders of Stock are entitled to notice, or whenever the Depositary and the Corporation shall decide it is
appropriate, the Depositary shall in each such instance fix a record date 

  
 13 

 
(which shall be the same date as the record date fixed by the Corporation with respect to, or otherwise in accordance with the terms of, the Stock, as identified in a written notice to the
Depositary of such record date) for the determination of the holders of Receipts who shall be entitled to receive such dividend, distribution, rights, preferences or privileges or the net proceeds of the sale thereof, or to give instructions for the
exercise of voting rights at any such meeting, or who shall be entitled to notice of such meeting or for any other appropriate reasons. 
  

	 	Section 4.5.	Voting Rights. 

 Subject
to the provisions of the Certificate of Designations, upon receipt of notice of any meeting at which the holders of Stock are entitled to vote, the Depositary shall, as soon as practicable thereafter, mail or transmit by such other method approved
by the Depositary, in its reasonable discretion, to the record holders of Receipts a notice prepared by the Corporation which shall contain (i) such information as is contained in such notice of meeting and (ii) a statement that the
holders may, subject to any applicable restrictions, instruct the Depositary as to the exercise of the voting rights pertaining to the amount of Stock represented by their respective Depositary Shares (including an express indication that
instructions may be given to the Depositary to give a discretionary proxy to a person designated by the Corporation) and a brief statement as to the manner in which such instructions may be given. Upon the written request of the holders of Receipts
on the relevant record date, the Depositary shall endeavor insofar as practicable to vote or cause to be voted, in accordance with the instructions set forth in such requests, the maximum number of whole shares of Stock represented by the Depositary
Shares evidenced by all Receipts as to which any particular voting instructions are received. The Corporation hereby agrees to take all reasonable action which may be deemed necessary by the Depositary in order to enable the Depositary to vote such
Stock or cause such Stock to be voted. In the absence of specific instructions from holders of Receipts, the Depositary will vote the Stock represented by the Depositary Shares evidenced by the Receipts of such holders proportionately with votes
cast pursuant to instructions received from the other holders. 
  

	 	Section 4.6.	Changes Affecting Deposited Securities and Reclassifications, Recapitalizations, etc. 

Upon any change in par or stated value, split-up, combination or any other reclassification of the Stock, subject to the Certificate of
Designations, or upon any recapitalization, reorganization, merger or consolidation affecting the Corporation or to which it is a party, the Corporation may, in its discretion and with the acknowledgement of the Depositary, (i) make such
adjustments as are certified by the Corporation in the fraction of an interest represented by one Depositary Share in one share of Stock and in the ratio of the redemption price per Depositary Share to the Redemption Price per share of Stock, in
each case as may be necessary fully to reflect the effects of such change in par or stated value, split-up, combination or other reclassification of the Stock, or of such recapitalization, reorganization, merger or consolidation and (ii) treat
any securities 

  
 14 

 
which shall be received by the Depositary in exchange for or upon conversion of or in respect of the Stock as new deposited securities so received in exchange for or upon conversion or in respect
of such Stock. In any such case, the Corporation may, in its discretion and with the acknowledgement of the Depositary, execute and deliver additional Receipts or may call for the surrender of all outstanding Receipts to be exchanged for new
Receipts specifically describing such new deposited securities. Anything to the contrary herein notwithstanding, Holders of Receipts shall have the right from and after the effective date of any such change in par or stated value, split-up,
combination or other reclassification of the Stock or any such recapitalization, reorganization, merger or consolidation to surrender such Receipts to the Depositary with instructions to convert, exchange or surrender the Stock represented thereby
only into or for, as the case may be, the kind and amount of shares and other securities and property and cash into which the Stock represented by such Receipts might have been converted or for which such Stock might have been exchanged or
surrendered immediately prior to the effective date of such transaction. 
  

	 	Section 4.7.	Delivery of Reports. 

 The
Depositary shall furnish to holders of Receipts any reports and communications received from the Corporation which are received by the Depositary and which the Corporation is required to furnish to the holders of the Stock. 

 

	 	Section 4.8.	Lists of Receipt Holders. 

Promptly upon request from time to time by the Corporation, the Depositary shall furnish to it a list, as of the most recent practicable
date, of the names, addresses and holdings of Depositary Shares of all record holders of Receipts. 
 ARTICLE V 

THE DEPOSITARY, THE DEPOSITARY’S 

AGENTS, THE REGISTRAR AND THE COMPANY 

 

	 	Section 5.1.	Maintenance of Offices, Agencies and Transfer Books by the Depositary; Registrar. 

Upon execution of this Deposit Agreement, the Depositary shall maintain at the Depositary’s Office, facilities for the execution and
delivery, registration and registration of transfer, surrender and exchange of Receipts, and at the offices of the Depositary’s Agents, if any, facilities for the delivery, registration of transfer, surrender and exchange of Receipts, all in
accordance with the provisions of this Deposit Agreement. 
 The Depositary shall keep books at the Depositary’s Office for
the registration and registration of transfer, surrender and exchange of Receipts, which books at all reasonable times shall be open for inspection by the record holders of Receipts; provided 

  
 15 

 
that any such holder requesting to exercise such right shall certify to the Depositary that such inspection shall be for a proper purpose reasonably related to such person’s interest as an
owner of Depositary Shares evidenced by the Receipts. 
 The Depositary may close such books, at any time or from time to time,
when deemed expedient by it in connection with the performance of its duties hereunder. 
 The Corporation may appoint a
Registrar for registration of the Receipts or the Depositary Shares evidenced thereby. If the Receipts or the Depositary Shares evidenced thereby or the Stock represented by such Depositary Shares shall be listed on one or more national securities
exchanges, the Corporation will appoint a Registrar for registration of such Receipts or Depositary Shares in accordance with any requirements of such exchange. Such Registrar (which may be the Depositary if so permitted by the requirements of any
such exchange) may be removed and a substitute Registrar appointed by the Depositary upon the request or with the approval of the Corporation. If the Receipts, such Depositary Shares or such Stock are listed on one or more other securities
exchanges, the Depositary will, at the request of the Corporation, arrange such facilities for the delivery, registration, registration of transfer, surrender and exchange of such Receipts, such Depositary Shares or such Stock as may be required by
law or applicable securities exchange regulation. 
  

	 	Section 5.2.	Prevention of or Delay in Performance by the Depositary, the Depositary’s Agents, the Registrar or the Company. 

Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the Corporation shall incur any liability to any holder of
any Receipt if by reason of any provision of any present or future law, or regulation thereunder, of the United States of America or of any other governmental authority or, in the case of the Depositary, the Depositary’s Agent or the Registrar,
by reason of any provision, present or future, of the Corporation’s Amended and Restated Certificate of Incorporation, as amended (including the Certificate of Designations), or by reason of any act of God or war or other circumstance beyond
the control of the relevant party, the Depositary, the Depositary’s Agent, the Registrar or the Corporation shall be prevented or forbidden from, or subjected to any penalty on account of, doing or performing any act or thing which the terms of
this Deposit Agreement provide shall be done or performed; nor shall the Depositary, any Depositary’s Agent, any Registrar or the Corporation incur liability to any holder of a Receipt (i) by reason of any nonperformance or delay, caused
as aforesaid, in the performance of any act or thing which the terms of this Deposit Agreement shall provide shall or may be done or performed, or (ii) by reason of any exercise of, or failure to exercise, any discretion provided for in this
Deposit Agreement except as otherwise explicitly set forth in this Deposit Agreement. 

  
 16 

	 	Section 5.3.	Obligations of the Depositary, the Depositary’s Agents, the Registrar and the Company. 

Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the Corporation assumes any obligation or shall be subject to
any liability under this Deposit Agreement to holders of Receipts other than for its negligence, willful misconduct or bad faith. Notwithstanding anything in this Deposit Agreement to the contrary, neither the Depositary, nor the Depositary’s
Agent nor any Registrar nor the Corporation shall be liable in any event for special, punitive, incidental, indirect or consequential losses or damages of any kind whatsoever (including but not limited to lost profits). 

Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the Corporation shall be under, any obligation to appear in,
prosecute or defend any action, suit or other proceeding in respect of the Stock, the Depositary Shares or the Receipts which in its opinion may involve it in expense or liability unless indemnity satisfactory to it against all expense and liability
be furnished as often as may be required. 
 Neither the Depositary nor any Depositary’s Agent nor any Registrar nor the
Corporation shall be liable for any action or any failure to act by it in reasonable reliance upon the written advice of legal counsel or accountants, or information from any person presenting Stock for deposit, any holder of a Receipt or any other
person believed by it in good faith to be competent to give such information. The Depositary, any Depositary’s Agent, any Registrar and the Corporation may each rely and shall each be protected in acting upon or omitting to act upon any written
notice, request, direction or other document believed by it to be genuine and to have been signed or presented by the proper party or parties. 
 The Depositary will indemnify the Corporation against any liability which may directly arise out of acts performed or omitted by the Depositary due to its gross negligence, willful misconduct or bad
faith, however, in no event shall the Depositary be liable for consequential, special or indirect damages of any kind regardless of whether the Depositary is put on notice of the possibility of such damages. The Depositary shall not be liable for
the acts or omissions due to the gross negligence, willful misconduct or bad faith of any Depositary’s Agent, so long as such Depositary’s Agent was appointed with due care. 

The Depositary shall not be responsible for any failure to carry out any instruction to vote any of the shares of Stock or for the manner
or effect of any such vote made, as long as any such action or non-action is not taken in bad faith. The Depositary undertakes, and any Registrar shall be required to undertake, to perform such duties and only such duties as are specifically set
forth in this Deposit Agreement, and no implied covenants or obligations shall be read into this Deposit Agreement against the Depositary or any Registrar. 
 The Depositary, the Depositary’s Agents, and any Registrar may own and deal in any class of securities of the Corporation and its affiliates and in Receipts. The Depositary may also act as transfer
agent or registrar of any of the securities of the Corporation and its affiliates. 

  
 17 

 The Depositary shall not be under any liability for interest on any monies at any time
received by it pursuant to any of the provisions of this Deposit Agreement or of the Receipts, the Depositary Shares or the Stock nor shall it be obligated to segregate such monies from other monies held by it, except as required by law. The
Depositary shall not be responsible for advancing funds on behalf of the Corporation and shall have no duty or obligation to make any payments if it has not timely received sufficient funds to make timely payments. 

In the event the Depositary believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or
other communication, paper or document received by the Depositary hereunder, or in the administration of any of the provisions of this Deposit Agreement, the Depositary shall deem it necessary or desirable that a matter be proved or established
prior to taking, omitting or suffering to take any action hereunder, the Depositary may, in its sole discretion upon written notice to the Corporation, refrain from taking any action and shall be fully protected and shall not be liable in any way to
the Corporation, any holders of Receipts or any other person or entity for refraining from taking such action, unless the Depositary receives written instructions or a certificate signed by the Corporation which eliminates such ambiguity or
uncertainty to the satisfaction of the Depositary or which proves or establishes the applicable matter to the satisfaction of the Depositary. The Depositary shall not be liable to the Corporation or any holder of Receipts, for any action taken by it
in accordance with the written instruction of the Corporation. 
  

	 	Section 5.4.	Resignation and Removal of the Depositary; Appointment of Successor Depositary. 

The Depositary may at any time resign as Depositary hereunder by delivering notice of its election to do so to the Corporation, such
resignation to take effect upon the appointment of a successor Depositary and its acceptance of such appointment as hereinafter provided. 
 The Depositary may at any time be removed by the Corporation by notice of such removal delivered to the Depositary, such removal to take effect upon the appointment of a successor Depositary hereunder and
its acceptance of such appointment as hereinafter provided. 
 In case at any time the Depositary acting hereunder shall resign
or be removed, the Corporation shall, within 60 days after the delivery of the notice of resignation or removal, as the case may be, appoint a successor Depositary, which shall be a bank or trust company having its principal office in the
United States of America and having a combined capital and surplus of at least $50,000,000. If no successor Depositary shall have been so appointed and have accepted appointment within 60 days after delivery of such notice, the resigning or
removed Depositary may petition any court of competent 

  
 18 

 
jurisdiction for the appointment of a successor Depositary. Every successor Depositary shall execute and deliver to its predecessor and to the Corporation an instrument in writing accepting its
appointment hereunder, and thereupon such successor Depositary, without any further act or deed, shall become fully vested with all the rights, powers, duties and obligations of its predecessor and for all purposes shall be the Depositary under this
Deposit Agreement, and such predecessor, upon payment of all sums due it and on the written request of the Corporation, shall promptly execute and deliver an instrument transferring to such successor all rights and powers of such predecessor
hereunder, shall duly assign, transfer and deliver all right, title and interest in the Stock and any moneys or property held hereunder to such successor, and shall deliver to such successor a list of the record holders of all outstanding Receipts
and such records, books and other information in its possession relating thereto. Any successor Depositary shall promptly mail or transmit by such other method approved by such successor Depositary, in its reasonable discretion, notice of its
appointment to the record holders of Receipts. 
 Any entity into or with which the Depositary may be merged, consolidated or
converted shall be the successor of such Depositary without the execution or filing of any document or any further act, and notice thereof shall not be required hereunder. Such successor Depositary may authenticate the Receipts in the name of the
predecessor Depositary or in the name of the successor Depositary. 
  

	 	Section 5.5.	Corporate Notices and Reports. 

 The Corporation agrees that it will deliver to the Depositary, and the Depositary will, promptly after receipt thereof, transmit to the record holders of Receipts, in each case at the addresses recorded
in the Depositary’s books, copies of all notices and reports (including without limitation financial statements) required by law, by the rules of any national securities exchange upon which the Stock, the Depositary Shares or the Receipts are
listed or by the Corporation’s Amended and Restated Certificate of Incorporation, as amended (including the Certificate of Designations), to be furnished to the record holders of Receipts. Such transmission will be at the Corporation’s
expense and the Corporation will provide the Depositary with such number of copies of such documents as the Depositary may reasonably request. In addition, the Depositary will transmit to the record holders of Receipts at the Corporation’s
expense such other documents as may be requested by the Corporation. 
  

	 	Section 5.6.	Indemnification by the Company. 

 Notwithstanding Section 5.3 to the contrary, the Corporation shall indemnify the Depositary, any Depositary’s Agent and any Registrar (including each of their officers, directors, agents and
employees) against, and hold each of them harmless from, any loss, damage, cost, penalty, liability or expense (including the reasonable out-of-pocket costs and expenses of defending itself) which may arise out of acts performed, suffered or omitted
to be taken in connection with this Deposit Agreement and the Receipts by the Depositary, any Registrar or any of their respective agents (including any Depositary’s Agent) and any transactions or documents contemplated hereby, except for any
liability 

  
 19 

 
arising out of negligence, willful misconduct or bad faith on the respective parts of any such person or persons. The obligations of the Corporation set forth in this Section 5.6 shall
survive any succession of any Depositary, Registrar or Depositary’s Agent. 
  

	 	Section 5.7.	Fees, Charges and Expenses. 

 The Corporation agrees promptly to pay the Depositary the compensation to be agreed upon with the Corporation for all services rendered by the Depositary hereunder and to reimburse the Depositary for its
reasonable out-of-pocket expenses (including reasonable counsel fees and expenses) incurred by the Depositary without negligence, willful misconduct or bad faith on its part (or on the part of any Depositary’s Agent) in connection with the
services rendered by it (or such Depositary’s Agent) hereunder. The Corporation shall pay all charges of the Depositary in connection with the initial deposit of the Stock and the initial issuance of the Depositary Shares, all withdrawals of
shares of the Stock by owners of Depositary Shares, and any redemption or exchange of the Stock at the option of the Corporation. The Corporation shall pay all transfer and other taxes and governmental charges arising solely from the existence of
the depositary arrangements. All other transfer and other taxes and governmental charges shall be at the expense of holders of Depositary Shares evidenced by Receipts. If, at the request of a holder of Receipts, the Depositary incurs charges or
expenses for which the Corporation is not otherwise liable hereunder, such holder will be liable for such charges and expenses; provided, however, that the Depositary may, at its sole option, require a holder of a Receipt to prepay the Depositary
any charge or expense the Depositary has been asked to incur at the request of such holder of Receipts. The Depositary shall present its statement for charges and expenses to the Corporation at such intervals as the Corporation and the Depositary
may agree. 
 ARTICLE VI 
 AMENDMENT AND TERMINATION 
  

	 	Section 6.1.	Amendment. 

 The form of
the Receipts and any provisions of this Deposit Agreement may at any time and from time to time be amended by agreement between the Corporation and the Depositary in any respect which they may deem necessary or desirable; provided, however, that no
such amendment which shall materially and adversely alter the rights of the holders of Receipts shall be effective unless such amendment shall have been approved by holders of Receipts representing in the aggregate at least two-thirds of the
Depositary Shares then outstanding. Every holder of an outstanding Receipt at the time any such amendment becomes effective shall be deemed, by continuing to hold such Receipt, to consent and agree to such amendment and to be bound by the Deposit
Agreement as amended thereby. In no event shall any amendment impair the right, subject to the provisions of Sections 2.5 and 2.6 and Article III, of any owner of Depositary Shares to surrender any Receipt evidencing such Depositary Shares to
the Depositary with instructions to deliver to the holder the Stock and all money and other 

  
 20 

 
property, if any, represented thereby, except in order to comply with mandatory provisions of applicable law or the rules and regulations of any governmental body, agency or commission, or
applicable stock exchange. 
  

	 	Section 6.2.	Termination. 

 This
Deposit Agreement may be terminated by the Corporation at any time upon not less than 60 days prior written notice to the Depositary, in which case, at least 30 days prior to the date fixed in such notice for such termination, the
Depositary will mail notice of such termination to the record holders of all Receipts then outstanding. 
 If any Receipts shall
remain outstanding after the date of termination of this Deposit Agreement, the Depositary thereafter shall discontinue the transfer of Receipts, shall suspend the distribution of dividends to the holders thereof and shall not give any further
notices (other than notice of such termination) or perform any further acts under this Deposit Agreement, except that the Depositary shall continue to collect dividends and other distributions pertaining to Stock, shall sell rights, preferences or
privileges as provided in this Deposit Agreement and shall deliver the number of whole or fractional shares of Stock and any money and other property, if any, represented by Receipts upon surrender thereof by the holders thereof. At any time after
the expiration of two years from the date of termination, the Depositary may sell Stock then held hereunder at public or private sale, at such places and upon such terms as it deems proper and may thereafter hold the net proceeds of any such sale,
together with any money and other property held by it hereunder, without liability for interest, for the benefit, pro rata in accordance with their holdings, of the holders of Receipts that have not theretofore been surrendered. After making such
sale, the Depositary shall be discharged from all obligations under this Deposit Agreement except to account for such net proceeds and money and other property and its obligations to the Corporation under Section 5.3. 

This Deposit Agreement will terminate automatically if (i) all outstanding Depositary Shares issued hereunder have been redeemed
pursuant to Section 2.8 or (ii) there shall have been made a final distribution in respect of the Stock in connection with any liquidation, dissolution or winding up of the Corporation and such distribution shall have been distributed to
the holders of Receipts representing Depositary Shares pursuant to Section 4.1 or 4.2, as applicable. 
 Upon the
termination of this Deposit Agreement, the Corporation shall be discharged from all obligations under this Deposit Agreement except for its obligations to the Depositary, any Depositary’s Agent and any Registrar under Sections 5.6 and 5.7.

  
 21 

 ARTICLE VII 
 MISCELLANEOUS 
  

	 	Section 7.1.	Counterparts. 

 This
Deposit Agreement may be executed in any number of counterparts, and by each of the parties hereto on separate counterparts, each of which counterparts, when so executed and delivered, shall be deemed an original, but all such counterparts taken
together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Deposit Agreement by facsimile or electronic mail shall be effective as delivery of a manually executed counterpart of this
Deposit Agreement. 
  

	 	Section 7.2.	Exclusive Benefit of Parties. 

 This Deposit Agreement is for the exclusive benefit of the parties hereto, and their respective successors hereunder, and shall not be deemed to give any legal or equitable right, remedy or claim to any
other person whatsoever. 
  

	 	Section 7.3.	Invalidity of Provisions. 

In case any one or more of the provisions contained in this Deposit Agreement or in the Receipts should be or become invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein or therein shall in no way be affected, prejudiced or disturbed thereby. 

 

	 	Section 7.4.	Notices. 

 Any and all
notices to be given to the Corporation hereunder or under the Receipts shall be in writing and shall be deemed to have been duly given if personally delivered or sent by mail, overnight delivery, or by telegram, facsimile transmission or electronic
mail confirmed by letter, addressed to the Corporation at: 
 EverBank Financial Corp 

501 Riverside Ave. 12th Floor 
 Jacksonville, Florida, 32202 
 Attention: Thomas A. Hajda, Executive Vice
President, General Counsel and Secretary 
 Facsimile No.: 904-623-8190 
 or at any other addresses of which the Company shall have notified the Depositary in writing. 
 Any and all notices to be given to the Depositary hereunder or under the Receipts shall be in writing and shall be deemed to have been duly given if personally delivered or

  
 22 

 
sent by mail, overnight delivery, or by facsimile transmission confirmed by letter, addressed to the Depositary at the Depositary’s Office at 

Wells Fargo Bank, N.A. 
 1110 Centre Pointe Curve, Suite 101 
 Mendota Heights, MN 55120-4100 

Attention: Relationship Manager 
 Facsimile No.: 651-450-4078 
 or at any other address of which the Depositary shall have notified
the Company in writing. 
 Except as otherwise provided herein, any and all notices to be given to any record holder of a
Receipt hereunder or under the Receipts shall be in writing and shall be deemed to have been duly given if personally delivered or sent by mail or facsimile transmission confirmed by letter, addressed to such record holder at the address of such
record holder as it appears on the books of the Depositary, or if such holder shall have timely filed with the Depositary a written request that notices intended for such holder be mailed to some other address, at the address designated in such
request. 
 Delivery of a notice sent by mail or by facsimile transmission shall be deemed to be effected at the time when a
duly addressed letter containing the same (or a confirmation thereof in the case of a facsimile transmission) is deposited, postage prepaid, in a post office letter box. The Depositary or the Corporation may, however, act upon any facsimile
transmission received by it from the other or from any holder of a Receipt, notwithstanding that such facsimile transmission shall not subsequently be confirmed by letter or as aforesaid. 

 

	 	Section 7.5.	Depositary’s Agents. 

The Depositary may from time to time appoint Depositary’s Agents to act in any respect for the Depositary for the purposes of this
Deposit Agreement and may at any time appoint additional Depositary’s Agents and vary or terminate the appointment of such Depositary’s Agents. The Depositary will promptly notify the Corporation in advance of any such action. 

 

	 	Section 7.6.	Appointment of Registrar and Transfer Agent in Respect of the Receipts. 

 The Corporation hereby appoints the Depositary as Registrar and Transfer Agent in respect of the Receipts and the Depositary hereby accepts such appointments. 

  
 23 

	 	Section 7.7.	Holders of Receipts Are Parties. 

 The holders of Receipts from time to time shall be parties to this Deposit Agreement and shall be bound by all of the terms and conditions hereof and of the Receipts by acceptance of delivery thereof.

  

	 	Section 7.8.	Governing Law. 

 This
Deposit Agreement and the Receipts and all rights hereunder and thereunder and provisions hereof and thereof shall be governed by, and construed in accordance with, the laws of the State of New York. Each party hereby agrees that any action,
suit or proceeding arising out of or relating to this Deposit Agreement or the Receipts, or such rights or provisions, may be brought in or removed to the U.S. District Court for the Southern District of New York or, if that court does not have
subject matter jurisdiction, any state court located in The City and County of New York. Each party hereby accepts, for itself and in respect of its property, generally and unconditionally, to submit to the non-exclusive jurisdiction of, and
venue in, such courts (and courts of appeals therefrom) with respect to any such action, suit or proceeding, and hereby waives the defenses of improper venue or inconvenient forum with respect thereto. 

 

	 	Section 7.9.	Inspection of Deposit Agreement. 

 Copies of this Deposit Agreement shall be filed with the Depositary and the Depositary’s Agents and shall be open to inspection during business hours at the Depositary’s Office and the
respective offices of the Depositary’s Agents, if any, by any holder of a Receipt. 
  

	 	Section 7.10.	Headings. 

 The headings
of articles and sections in this Deposit Agreement and in the form of the Receipt set forth in Exhibit A hereto have been inserted for convenience only and are not to be regarded as a part of this Deposit Agreement or the Receipts or to have
any bearing upon the meaning or interpretation of any provision contained herein or in the Receipts. 
  

	 	Section 7.11.	Confidentiality. 

 The
Depositary and the Corporation agree that all books, records, information and data pertaining to the business of the other party, including, inter alia, personal, non-public Holder information, which are exchanged or received pursuant to the
negotiation or the carrying out of this Deposit Agreement, shall remain confidential, and shall not be voluntarily disclosed to any other person, except as may be required by law or legal process. 

  
 24 

 IN WITNESS WHEREOF, the Company and the Depositary have duly executed this Agreement as of
the day and year first above set forth, and all holders of Receipts shall become parties hereto by and upon acceptance by them of delivery of Receipts issued in accordance with the terms hereof. 

 

					
	EVERBANK FINANCIAL CORP
		
	By:	 	 /s/ Thomas A. Hajda

		 	Name:	 	Thomas A. Hajda
		 	Title:	 	Executive Vice President, Secretary and General Counsel
	
	WELLS FARGO BANK, N.A.
		
	By:	 	 /s/ Patti Boyd

		 	Name:Patti Boyd
		 	Title:Assistant Vice President

  
 25 

 EXHIBIT A 

[FORM OF FACE OF RECEIPT] 

[Unless this receipt is presented by an authorized representative of The Depository Trust Company, a New York corporation (“DTC”), to EverBank
Financial Corp or its agent for registration of transfer, exchange, or payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as is requested by an authorized representative of DTC (and any payment
is made to Cede & Co. or to such other entity as is requested by an authorized representative of DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof,
Cede & Co., has an interest herein.] 
 DEPOSITARY SHARES 

[                    ] 

DEPOSITARY RECEIPT FOR DEPOSITARY SHARES EACH 
 REPRESENTING 1/1,000TH OF ONE SHARE OF 6.75% SERIES A NON-CUMULATIVE PERPETUAL 

PREFERRED STOCK 

OF 
 EVERBANK
FINANCIAL CORP 
 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 

CUSIP [                    ]

 SEE REVERSE FOR CERTAIN DEFINITIONS 
 Dividend Payment Dates: January 5, April 5, July 5 and October 5 of each year commencing on
[                    ] 

Wells Fargo Bank, N.A., a national banking association formed under the laws of the United States, as Depositary (the
“Depositary”), hereby certifies that Cede & Co. is the registered owner of [                ]
[                ] DEPOSITARY SHARES (“Depositary Shares”), each Depositary Share representing 1/1,000th of one share of 6.75% Series A Non-Cumulative
Perpetual Preferred Stock, $0.01 par value, with a liquidation preference $25,000 per share, (the “ Stock ”), of EverBank Financial Corp, a Delaware corporation (the “ Corporation ”), on deposit with the Depositary,
subject to the terms and entitled to the benefits of the Deposit Agreement dated as of November 13, 2012 (the “ Deposit Agreement ”), among the Corporation, the Depositary and the holders from time to time of the Depositary
Receipts. By accepting this Depositary Receipt, the holder hereof becomes a party to and agrees to be bound by all the terms and conditions of the Deposit Agreement. This Depositary Receipt shall not be valid or obligatory for any purpose or
entitled to any benefits under the Deposit Agreement unless it shall have been executed by the Depositary by the manual signature of a duly authorized officer or, if executed in facsimile by the Depositary, countersigned by a Registrar in respect of
the Depositary Receipts by the manual signature of a duly authorized officer thereof. 

  
 A-1

 This Depositary Receipt is transferable in New York, New York. 

Dated: [                    ] 

 

			
	Wells Fargo Bank, N.A., as Depositary
		
	By:	 	  

		 	Authorized Officer

  
 A-2

 [FORM OF REVERSE OF RECEIPT] 

 
  

EVERBANK FINANCIAL CORP 
 THE CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH HOLDER OF A RECEIPT WHO SO REQUESTS A COPY OF THE DEPOSIT AGREEMENT AND A COPY OR SUMMARY OF THE CERTIFICATE OF DESIGNATIONS ESTABLISHING THE 6.75%
SERIES A NON-CUMULATIVE PERPETUAL PREFERRED STOCK OR OF EACH OTHER CLASS OF STOCK OR SERIES THEREOF OF THE CORPORATION. ANY SUCH REQUEST IS TO BE ADDRESSED TO THE DEPOSITARY NAMED ON THE FACE OF THIS RECEIPT. 

 
  
 EXPLANATION OF ABBREVIATIONS 
 The following abbreviations when used in the form
of ownership on the face of this certificate shall be construed as though they were written out in full according to applicable laws or regulations. Abbreviations in addition to those appearing below may be used. 

 

							
	 Abbreviation
	  	 Equivalent Phrase
	  	 Abbreviation
	  	 Equivalent Phrase

	JT TEN	  	As joint tenants, with right of survivorship and not as tenants in common	  	TEN BY ENT	  	As tenants by the entireties
				
	TEN IN COM	  	As tenants in common	  	UNIF GIFT MIN ACT	  	Uniform Gifts to Minors Act

  

											
	 Abbreviation
	  	 Equivalent Word
	  	 Abbreviation
	  	 Equivalent Word
	  	 Abbreviation
	  	 Equivalent Word

	ADM	  	Administrator(s), Administratrix	  	EX	  	Executor(s), Executrix	  	PAR	  	Paragraph
						
	AGMT	  	Agreement	  	FBO	  	For the benefit of	  	PL	  	Public Law
						
	ART	  	Article	  	FDN	  	Foundation	  	TR	  	(As) trustee(s), for, of
						
	CH	  	Chapter	  	GDN	  	Guardian(s)	  	U	  	Under
						
	CUST	  	Custodian for	  	GDNSHP	  	Guardianship	  	UA	  	Under agreement
						
	DEC	  	Declaration	  	MIN	  	Minor(s)	  	UW	  	Under will of, Of will of, Under last will & testament
						
	EST	  	Estate, of Estate of	  		  		  		  	

  
 A-3

 For value received,
                    hereby sell(s), assign(s) and transfer(s) unto 
 PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE 
 PLEASE PRINT
OR TYPEWRITE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE 
 Depositary Shares represented by the within Receipt, and
do(es) hereby irrevocably constitute and appoint                                 
Attorney to transfer the said Depositary Shares on the books of the within named Depositary with full power of substitution in the premises. 

Dated:                      

 

			
		  	 NOTICE: The signature to the assignment must correspond with the name as written upon the face of this Receipt in every particular, without alteration or
enlargement or any change whatsoever.

 SIGNATURE GUARANTEED 
 NOTICE: The signature(s) should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan associations, and credit unions with membership in an approved signature guarantee
medallion program), pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934. 

  
 A-4

 EXHIBIT B 

Certificate of Designations 

  
 B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]